

THE UNIVERSITY of EDINBURGH

# Edinburgh Research Explorer

# The confounding effects of high genetic diversity on the determination and interpretation of differential gene expression analysis in the parasitic nematode Haemonchus contortus

## Citation for published version:

Rezansoff, AM, Laing, R, Martinelli, A, Stasiuk, S, Redman, E, Bartley, D, Holroyd, N, Devaney, E, Sargison, ND, Doyle, S, Cotton, JA & Gilleard, JS 2019, 'The confounding effects of high genetic diversity on the determination and interpretation of differential gene expression analysis in the parasitic nematode Haemonchus contortus', *International Journal For Parasitology*, vol. 49, no. 11. https://doi.org/10.1016/j.ijpara.2019.05.012

# **Digital Object Identifier (DOI):**

10.1016/j.jpara.2019.05.012

#### Link:

Link to publication record in Edinburgh Research Explorer

**Document Version:** Peer reviewed version

Published In: International Journal For Parasitology

#### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

#### Take down policy

The University of Édinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



#### Elsevier Editorial System(tm) for International Journal for Parasitology Manuscript Draft

Manuscript Number: IJPara19 132R1

Title: The confounding effects of high genetic diversity on the determination and interpretation of differential gene expression analysis in the parasitic nematode Haemonchus contortus

Article Type: Full Length Article

Keywords: Haemonchus contortus; Transcriptomics; RNAseq; Differential Expression; Ivermectin; Anthelmintic Resistance

Corresponding Author: Professor John Gilleard, BVSc PhD DipEVPC MRCVS

Corresponding Author's Institution: University of Calgary, Fac. Vet. Med.

First Author: Andrew M Rezansoff

Order of Authors: Andrew M Rezansoff; Roz Laing; Axel Martinelli; Susan Stasiuk, PhD; Elizabeth Redman; Dave Bartley; Nancy Holroyd; Eileen Devaney; Stephen Doyle; Neil D Sargison; James Cotton; John S Gilleard

Manuscript Region of Origin: CANADA

Abstract: Differential expression analysis between parasitic nematode strains is commonly used to implicate candidate genes in anthelmintic resistance or other biological functions. We have tested the hypothesis that the high genetic diversity of an organism like Haemonchus contortus could complicate such analyses. First, we investigated the extent to which sequence polymorphism affects the reliability of differential expression analysis between the genetically divergent H. contortus strains MHco3(ISE), MHco4(WRS) and MHco10(CAVR). Using triplicates of 20 adult female worms from each population isolated under parallel experimental conditions, we found that high rates of sequence polymorphism in RNAseq reads were associated with lower efficiency read mapping to gene models under default TopHat2 parameters, leading to biased estimates of inter-strain differential expression. We then showed it is possible to largely compensate for this bias by optimizing the read mapping SNP allowance and filtering out genes with particularly high SNP rates. Once the sequence polymorphism biases were removed, we then assessed the genuine transcriptional diversity between the strains, finding  $\geq$  824 differentially expressed genes across all three pairwise strain comparisons. This high level of inter-strain transcriptional diversity not only suggests substantive inter-strain phenotypic variation but also highlights the difficulty of reliably associating differential expression of specific genes with phenotypic differences. To provide a practical example, we analyzed two gene families of potential relevance to ivermectin drug resistance; the ABC transporters and the ligand-gated ion channels (LGICs). Over half of genes identified as differentially expressed using default TopHat2 parameters were shown to be an artifact of sequence polymorphism differences. This work illustrates the need to account for sequence polymorphism in differential expression analysis. It also demonstrates that a large number of genuine transcriptional differences can occur between H. contortus strains and these must be

considered before associating the differential expression of specific genes with phenotypic differences between strains.



John Gilleard, BVSc, PhD, DipACVM, DipEVPC, MRCVS Associate Dean, Research Professor, Molecular Parasitology Faculty of Veterinary Medicine TRW 2D10, 3280 Hospital Drive NW Calgary, Alberta T2N 4Z6

> Telephone: +1-403-210-6327 Email: jsgillea@ucalgary.ca

> > May 17, 2019

Dear Dr Loukas,

Thank you for your consideration of our manuscript IJPara19\_132 for publication in the International Journal for Parasitology entitled *"The confounding effects of high genetic diversity on the determination and interpretation of differential gene expression analysis in the parasitic nematode Haemonchus contortus"*. We appreciate the positive evaluation of our manuscript and thank you and the referees for the constructive feedback provided. We submit a revised manuscript, together with a line-by-line response to the reviewers' comments

We hope the changes made to this section are satisfactory.

We thank you for considering this revised manuscript and hope it is now considered suitable for publication.

Yours sincerely,

J.S. hull

Prof John Gilleard



John Gilleard, BVSc, PhD, DipACVM, DipEVPC, MRCVS Associate Dean, Research Professor, Molecular Parasitology Faculty of Veterinary Medicine TRW 2D10, 3280 Hospital Drive NW Calgary, Alberta T2N 426

> Telephone: +1-403-210-6327 Email: jsgillea@ucalgary.ca

> > May 17, 2019

Dear Dr Loukas,

Thank you for your consideration of our manuscript IJPara19\_132 for publication in the International Journal for Parasitology entitled *"The confounding effects of high genetic diversity on the determination and interpretation of differential gene expression analysis in the parasitic nematode Haemonchus contortus"*. We appreciate the positive evaluation of our manuscript and thank you and the referees for the constructive feedback provided. We submit a revised manuscript, together with a line-by-line response to the reviewers' comments and an itemized list of modifications to the revised manuscript. The reviewer comments are included in *italics* and our response in non-italicized text. The line numbers referred to in our responses refer to those of the revised manuscript.

# <u>Reviewer 1</u>

We thank the reviewer for their very positive view and constructive feedback of the manuscript.

We have addressed the reviewers points as follows:

Reviewer comment 1: Abstract: lines 29-37. It is important to have some statement in here about what lifestage(s), age, sex, host, method of worm collection etc were used to ensure that it's a level playing field at the start - e.g. that you're not comparing MHco3 L3s that have been kept in a fridge for a year with adult female MHco10 straight out of an abomasum.

Response: Line 32 - We have inserted a comment describing the experimental samples to clarify the controlled nature of RNAseq experiment from the abstract onward. We also made some minor grammatical changes to the abstract to maintain its length below 300 words again.

*Reviewer comment 2: Figure 2C, the labelling on the x axis could be clearer - i.e. leave more room between the labels* 

Response: We have condensed Figure 2C X-axis labels to increase the space between them as requested.

# **Reviewer 2**

We have addressed the reviewers points as follows:

Reviewer comment 1: This interesting manuscript makes the case that simply using the default setting on the most commonly used suite of programs for the analysis of RNASeq data can lead to serious errors in the estimation of changes in gene expression between strains and isolates. The authors specifically looked at Haemonchus contortus, though presumably the point is also valid for many other parasites in which drug resistance, or another important biological variable, is a problem.

Response: We thank the reviewer for their positive comments

Reviewer comment 2: With such papers it is essentially impossible to judge the quality of the experimental approach; this is an excellent and reputable group so I would not expect there to be any problems.

Response: We thank the reviewer for their supportive comments

Reviewer comment 3: The authors cite several previous reports in their critique of the existing literature, however at least some of these use qPCR rather than RNASeq data, and so the criticism may not be valid. Would they expect qPCR to be equally prone to these artefactual differences between strains - perhaps not assuming that the primer sequences are conserved. If that were not the case it might be that the amplifications would fail? Some discussion of this point might be valuable.

Response: Line 391 – We understand the reviewer's point here and have added a comment to the Discussion section to make it more clear that we are suggesting high genetic diversity is a problem when conducting RNAseq experiments specifically.

*Reviewer comment 4: This may be an odd statement after the previous point, but overall I found the discussion to be overlong and repetitive of points made elsewhere - it could be considerably shortened with no loss of impact.* 

We would prefer to retain the current Discussion as it draws together the key messages from the Results. The paper is quite technical in nature and a shortened high-level Discussion would make it difficult for readers to follow how the conclusions were supported.

*Reviewer comment 5: The number of reads mapping to the H. contortus genome assembly seems a little low (60-70%, depending on strain). Did the authors check for host or bacterial contamination of their sequences?* 

Response: The mapping success rates of the samples we observed for all three strains were similar to mapping statistics of other *H. contortus* samples that we and others have worked with in the past

(~50-75% mapping success rates is typical for *H. contortus*). Further our map rates among the three triplicates of the same strain were very similar for all three strains, which reasonably suggests that there is no single triplicate that has a low mapping success rate because of contamination.

*Reviewer comment 6: Some of the values on the axes of Fig 3 are rather small and faint, and may not reproduce well especially if they are reduced in size.* 

Response: We have increased the font size of the number labels on both axis of Figure 3 as requested.

Reviewer comment 7: Though 'N' is defined in the Methods, this may be easy for the more casual reader to overlook. Given its central importance to the arguments in the manuscript, it may be worth restating what this value represents in the Results or Discussion, perhaps relating it to the observed level of polymorphism between H. contortus strains.

Response: Lines 209, 213, 214 – We have redefined what N2, N5, and N10 represent when they are first mentioned in the Results. N2 and N5 were also redefined on Lines 411 and 412 of the Discussion section.


We hope the changes made to this section are satisfactory.

We thank you for considering this revised manuscript and hope it is now considered suitable for publication.

Yours sincerely,

J.S. hull

Prof John Gilleard



# Paper Highlights

- Sequence polymorphism can counfound RNAseq analysis in genetically diverse organisms due to read mapping biases
- Optimizing read mapping allowances and excluding highly polymorphic genes reduces differential gene expression analysis biases
- Genetically divergent strains of *H. contortus* have very high levels of inter-strain transcriptional diversity
- Interpretation of inter-strain differential gene expression needs to consider sequence polymorphism and overall transcriptional diversity

1	The confounding effects of high genetic diversity on the determination and interpretation of differential
2	gene expression analysis in the parasitic nematode Haemonchus contortus
3	
4	
5	Andrew M. Rezansoff <sup>a</sup> , Roz Laing <sup>b</sup> , Axel Martinelli <sup>c</sup> , Susan Stasiuk <sup>a</sup> , Elizabeth Redman <sup>a</sup> , Dave
6	Bartley <sup>d</sup> , Nancy Holroyd <sup>c</sup> , Eileen Devaney <sup>b</sup> , Neil D. Sargison <sup>e</sup> , Stephen Doyle <sup>c</sup> , James Cotton <sup>c</sup> , John S.
7	Gilleard <sup>a*</sup>
8	
9	<sup>a</sup> Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine,
10	University of Calgary, Alberta, Canada
11	<sup>b</sup> Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary
12	and Life Sciences, University of Glasgow, Scotland, United Kingdom
13	<sup>c</sup> Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, United Kingdom
14	<sup>d</sup> Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, United
15	Kingdom
16	<sup>e</sup> University of Edinburgh, Royal (Dick) School of Veterinary Studies, Easter Bush Veterinary Centre,
17	Roslin, Midlothian, EH25 9RG, United Kingdom.
18	
19	
20	
21	* Corresponding author: Professor John Gilleard, Department of Comparative Biology and
22	Experimental Medicine, Faculty of Veterinary Medicine,
23	3330, Hospital Drive, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
24	Tel: (403) 210 6327, Fax: (403) 210 7882, email: jsgillea@ucalgary.ca

# 25 Abstract

26

27 Differential expression analysis between parasitic nematode strains is commonly used to implicate 28 candidate genes in anthelmintic resistance or other biological functions. We have tested the hypothesis 29 that the high genetic diversity of an organism like Haemonchus contortus could complicate such 30 analyses. First, we investigated the extent to which sequence polymorphism affects the reliability of 31 differential expression analysis between the genetically divergent *H. contortus* strains MHco3(ISE), 32 MHco4(WRS) and MHco10(CAVR). Using triplicates of 20 adult female worms from each population 33 isolated under parallel experimental conditions, we found that high rates of sequence polymorphism in 34 RNAseq reads were associated with lower efficiency read mapping to gene models under default 35 TopHat2 parameters, leading to biased estimates of inter-strain differential expression. We then showed 36 it is possible to largely compensate for this bias by optimizing the read mapping SNP allowance and 37 filtering out genes with particularly high SNP rates. Once the sequence polymorphism biases were 38 removed, we then assessed the genuine transcriptional diversity between the strains, finding  $\geq 824$ 39 differentially expressed genes across all three pairwise strain comparisons. This high level of inter-40 strain transcriptional diversity not only suggests substantive inter-strain phenotypic variation but also 41 highlights the difficulty of reliably associating differential expression of specific genes with phenotypic 42 differences. To provide a practical example, we analyzed two gene families of potential relevance to 43 ivermectin drug resistance; the ABC transporters and the ligand-gated ion channels (LGICs). Over half 44 of genes identified as differentially expressed using default *TopHat2* parameters were shown to be an 45 artifact of sequence polymorphism differences. This work illustrates the need to account for sequence polymorphism in differential expression analysis. It also demonstrates that a large number of genuine 46

transcriptional differences can occur between *H. contortus* strains and these must be considered before
associating the differential expression of specific genes with phenotypic differences between strains.

Keywords: *Haemonchus contortus*; Transcriptomics; RNAseq; Differential Expression; Ivermectin;
Anthelmintic Resistance

52

# 53 **1. Introduction**

54

55 RNAseq has become the standard approach for the genome-wide analysis and quantification of 56 gene expression across the life sciences (Conesa et al., 2016; Wang et al., 2009). Established sequence 57 aligners used in RNAseq analysis pipelines, such as *TopHat2* and its faster successor *HISAT2* were 58 developed, and their default mapping parameters set, primarily for use on vertebrate species such as 59 humans, mouse, and zebrafish, which have relatively low levels of both intra- and inter-population 60 genetic diversity (Baruzzo et al., 2017; Guryev et al., 2006; Lindblad-Toh et al., 2000; Wang, 1998). 61 Further, until relatively recently, applications of RNAseq to non-vertebrate species were largely 62 confined to laboratory strains of model organisms such as Drosophila melanogaster and 63 Caenorhabditis elegans, which also have relatively low levels of genetic diversity (Andersen et al., 64 2012; Cingolani et al., 2012). Consequently, most publications make little or no acknowledgement of 65 the potentially confounding effects of sequence polymorphism on the mapping efficiency of RNAseq 66 reads and the calling of differentially expressed genes (Baruzzo et al., 2017). RNAseq analysis pipelines are generally applied to non-model organisms simply using established default parameters, 67 68 with no consideration given the level and distribution of sequence polymorphism within, and between 69 the strains or populations being compared (Antony et al., 2016; Croken et al., 2014; Edwards et al.,

70	2013; Fiebig et al., 2015; Papenfort et al., 2015). However, many taxa show high levels and complex
71	patterns of intra-species genetic diversity (Blumenthal and Davis, 2004; Dey et al., 2013; Redman et
72	al., 2015; Romiguier et al., 2014). This is a concern since standard RNAseq alignment benchmarking
73	studies have shown that the performance of different sequence aligners varies with the genome
74	complexity and levels of sequence polymorphism when using simulated sequence data (Baruzzo et al.,
75	2017). However, no published experimental studies directly examine the effects of sequence
76	polymorphism on differential expression analyses using commonly applied RNAseq analysis pipelines.
77	A good example of the application of RNAseq analysis to non-model organisms is for the
78	investigation of differential expression of candidate genes potentially involved in anthelmintic drug
79	resistance in parasitic nematodes (Dicker et al., 2011; El-Abdellati et al., 2011; Urdaneta-Marquez et
80	al., 2014; Williamson et al., 2011; Xu et al., 1998). Haemonchus contortus is arguably the most
81	established parasitic nematode model used for such studies (Gilleard, 2013). It has a good quality
82	reference genome and has extremely high levels of sequence polymorphism (upwards of 5% SNP
83	rates), both within and between strains or geographical isolates (Gilleard and Redman, 2016; Laing et
84	al., 2013). Consequently, it is an excellent system in which to study the potentially confounding effects
85	of sequence polymorphism on differential expression analysis. In this paper, we use three well
86	characterized laboratory passaged strains of <i>H. contortus</i> to examine how differences in coding
87	sequence (CDS) polymorphism rates, with respect to the MHco3(ISE) genome reference strain, affect
88	read mapping and bias differential expression analysis. We show how these confounding effects can be
89	reduced and demonstrate that, even when the effects of sequence polymorphism are minimized, there
90	are still a large number of differentially expressed genes between these three strains. These results have
91	important implications for the application of RNAseq analysis to many non-model organism species
92	with high levels of genetic diversity.

# 94 2. Materials & Methods

95

93

96

2.1 H. contortus strains, sample preparation, and sequencing.

97

98 The MHco3(ISE), MHco4(WRS) and MHco10(CAVR) *H. contortus* strains have been previously 99 characterised and are described in detail elsewhere (Laing et al., 2013; Redman et al., 2012, 2008). The 100 MHco3(ISE) is susceptible to all main classes of anthelmintic and has been used as the reference 101 genome strain (Laing et al., 2013). The MHco4(WRS) strain is derived from the White River Strain 102 (WRS) that was isolated as an ivermectin resistant field isolate from South Africa (Van Wyk and 103 Malan, 1988). The MHco10(CAVR) strain is derived from the Chiswick Avermectin Resistant Strain 104 (CAVR) which was originally isolated as an ivermectin resistant strain as a laboratory contaminant of a 105 field isolate from Australia (Le Jambre et al., 1995). 106 Three sets of 20 adult female worms were recovered on necropsy at 28 days post experimental 107 infection from the abomasa of three different individual sheep for each H. contortus strain; 108 MHco3(ISE), MHco4(WRS), and MHco10(CAVR). Each set of 20 adult females served as one of 109 three biological replicates for RNAseq analysis for each strain. Adult worms recovered from the abomasum were rinsed and sexed in physiological saline at 37°C and then immediately snap frozen 110 111 before total RNA was isolated from each pool of 20 worms using a standard Trizol protocol as 112 described in Laing et al., (2011). RNA samples were assessed on a Bioanalyser 2100 (Agilent) and 113 Illumina transcriptome libraries were prepared as previously described (Laing et al., 2011). Sequencing 114 of transcriptome libraries was performed on an Illumina HiSeq platform to generate 100 bp paired-end 115 reads.

# 2.2 Sequence quality control and read mapping.

119	Raw 100 bp reads were inspected using FastQC (Andrews, 2010) for overall dataset integrity and
120	all reads were trimmed at the 5' end by ten bases. Fifteen bases were also trimmed from the 3' ends of
121	all reads to remove low quality sequence characteristic of 3' tail ends. The post-trimmed 75 base-pair
122	reads were used for mapping to the H. contortus MHco3(ISE) reference genome assembly (Laing et al.,
123	2013) with TopHat2 (Dobin and Gingeras, 2013). The assembly used is an improved version (N50 of
124	5.24 MB) of the original published H. contortus genome assembly (GenBank ID PRJEB506 - N50 of
125	83.29 kb (Laing et al., 2013)) and contains an expanded set of annotated gene models
126	(https://data.mendeley.com/drafts/4z6xv5j5zf). Numerical identifiers of these additional gene models
127	begin with HCOI_0500, and have not yet been submitted to online genomic resources (e.g.
128	Uniprot.org).
129	TopHat2 was executed using the following parameter settings: TopHat2 -N (#)read-gap-length
130	(%)read-edit-dist (# + %) -I 40000 -r 200 -a 6 -g 1no-discordantno-mixedmin-intron 10
131	microexon-searchmate-std-dev 50library-type fr-unstranded /reference.fasta
132	trimmed_forward_reads.fastq trimmed_reverse_reads.fastq. Only -N (specifying the number of SNPs
133	per mapped read allowed by TopHat2),read-gap-length (the allowed base count of any indels), and
134	read-edit-dist (the allowed combined base count of both -N andread-gap-length) were adjusted
135	throughout the experiment. Reads of all triplicates of all three populations were initially mapped with
136	TopHat2 using a scale of SNP (polymorphism) allowances from 2 to 10 SNPs (-N) per read with indel
137	allowance (read-gap-length) held constant at 3 bases.

138	Three different allowances for polymorphism were then subsequently chosen for further analysis:
139	low, the TopHat2 default allowances (denoted N2 – allowing 2 SNPs or 2 indels per read), moderate
140	(denoted N5 - allowing 5 SNPs and 3 indels per read), and high (denoted N10 - allowing 10 SNPs and
141	6 indels per read) allowances for polymorphism respectively. Varying the indel allowances had very
142	little effect on the percentage of reads mapping to the reference genome (data not shown). Samtools'
143	flagstat tool (Li et al., 2009) was used to determine the proportion of reads mapped at each allowance
144	for each strain.
145	
146	2.3 RNAseq processing and analysis.
147	
148	Reads mapped to each gene model were sorted with samtools sort, and counted for each of the
149	three bioreplicates for each strain at the three different SNP allowances – N2, N5, N10 – using the
150	following command in HTseq-count: htseq-count -i parent -q -s no -f bam -t cds
151	./sorted_accepted_hits.bam ./genome_annotation_file.gff3 (Anders et al., 2014). Raw mapped read
152	counts for each gene model of each bioreplicate of each strain were compiled and used as input for
153	DESeq2.
154	DESeq2 (Love et al., 2014) was run in Rstudio (2015) to identify differential expression between
155	the three strains, at different polymorphism allowances, based on gene model read counts. DESeq2's
156	plotPCA tool was used to plot segregation of triplicates based on gene expression of the top 15,000
157	expressed low-polymorphic genes at the moderate N5 allowance. DESeq2 result tables were exported
158	and manipulated in MS Excel. Genes were only called as differentially expressed in this analysis if they
159	1) showed a greater than 2 fold-change difference in expression between the strains compared, and 2)
160	yielded adjusted p-values of less than 0.05.

162

2.4 Categorizing gene models on the basis of SNP rates and SNP rate differences between strains

163

164 SNPs within coding regions (CDS) were called using samtools mpileup on whole genome 165 sequence (WGS) datasets created for each of the strains against the MHco3(ISE) genome assembly 166 (Doyle et al., 2019). SNPs present at > 40% frequency were totaled per gene model for each of the 167 strains. The SNP rate was calculated for each gene in each strain by dividing the total number of SNPs 168 in the gene by the respective gene model CDS length. The genes were then categorized in two different 169 ways for subsequent investigation of the effect of sequence polymorphism on read mapping and 170 RNAseq analysis. First, they were categorized based on their SNP rates in each strain: categories 0%, 171 0-0.5%, 0.5-1%, 1-2%, 2-5%, and > 5%. Second, they were categorized based on the difference in SNP 172 rates for each of the three pairwise strain comparisons (i.e. the SNP rate observed in one strain 173 subtracted by the SNP rate observed in the other) categories >5-15%, >2-5%, >0-2%, 0%. Genes with a 174 >15% difference and were not categorized as they were likely to be due to annotation errors and/or 175 overly short CDS lengths. 176

177 2.5 Assessment of genuine transcriptomic variation between the strains.

178

179 Differential expression statistics were called with *DESeq2* for each of the three pairwise strain 180 comparisons at each of the three map allowances. In each pairwise strain comparison at the N5 allowance, genes showing low SNP rate differences (less than 2%) were denoted as low-polymorphic 181 182 genes (LPGs). The number of low-polymorphic genes up- and down-regulated in each strain 183 comparison at the N5 allowance, and shared up- or down-regulated in two strains vs. the third strain,

184	were totaled at both a log2 1X and log2 2X fold-change expression threshold. Candidate anthelmintic
185	resistance gene families, as defined by the published <i>H. contortus</i> genome annotation (Laing et al.,
186	2013), were specifically highlighted in that their differential expression was compared at the N2
187	allowance, the N5 allowances, and the N5 allowance with high-polymorphic genes removed.
188	Gene ontological classifications were obtained from UniProt.org (The UniProt Consortium, 2015)
189	for <i>H. contortus</i> gene models of the originally published annotation (Laing et al., 2013). Low
190	polymorphic genes with ontological classifications were used as the reference gene set against which
191	enrichment was assessed. Functional enrichment was called in genes > log2 1X fold-change
192	differentially expressed in each pairwise, and each shared strain comparison. FunRich (Pathan et al.,
193	2015) was used to call enriched gene ontological classes using a statistical significance threshold of
194	Benjamini-Hochberg corrected FDR adjusted p-values < 0.05.
195	
196	3. Results
197	
198	3.1 Coding sequence polymorphism affects RNAseq read mapping against the MHco3(ISE)
199	reference assembly for the three different H. contortus strains.
200	
201	The total combined read counts of the triplicate RNAseq datasets were similar among the three
202	strains at 36,175,121, 36,025,170, and 37,584,775 reads for MHco3(ISE), MHco4(WRS), and
203	MHco10(CAVR) respectively. We determined the total number of CDS SNPs present at $> 40\%$
204	frequency, relative to the MHco3(ISE) reference genome assembly, using whole genome sequence
205	datasets independently created for each strain. A total of 701,715, 1,121,242 and 1,143,102 CDS SNPs,

representing rates of 2.97%, 4.74% and 4.84% of the 23.63 Mb *H. contortus* reference CDS annotation,
were present for MHco3(ISE), MHco4(WRS), and MHco10(CAVR) respectively.

208 The percentage of RNAseq reads that mapped to the MHco3(ISE) reference genome assembly,

using the default SNP allowance (N2 – allowing 2 SNPs or 2 indels per read) in *TopHat2*, was 60.7%,

210 44.8% and 47.1% for the MHco3(ISE), MHco4(WRS) and MHco10(CAVR) strains respectively (Fig.

1). Increasing the *TopHat2* SNP allowance parameter changed the percentage of RNAseq reads that

212 mapped (Fig. 1). For the MHco3(ISE) strain, the percentage of RNAseq reads mapping to the reference

213 genome increased as the polymorphism allowance was increased from N2 to N5 (allowing 5 SNPs and

214 3 indels per read) and then decreased as the allowance was further increased to N10 (allowing 10 SNPs

and 6 indels per read) (Fig. 1). This pattern was very similar for the MHco4(WRS) and

216 MHco10(CAVR) strains but the maximum percentage of reads mapping occurred at the N6 allowance,

albeit at rates only 0.1% greater than at N5 (Fig. 1). The percentage of RNAseq reads that mapped to
the reference MHco3(ISE) genome assembly was greater for the MHco3(ISE) strain than for the other
two strains at all polymorphism allowances, although the magnitude of this difference decreased from

two situatis at an porymorphism anowallees, attrough the magnitude of this affective decreasedthe N2 to N10 allowance (Fig. 1).

A more detailed analysis was undertaken for the N2, N5 and N10 polymorphism allowances at the level of gene models. Increasing the polymorphism allowance from N2 to N5 resulted in 12,778, 11,101, and 11,324 gene models having a >1% increase in the number of mapped RNAseq reads for

224 MHco3(ISE), MHco4(WRS), and MHco10(CAVR) respectively (Fig. 2A, panel i). In contrast, 591,

1,316, and 1,563 genes showed a >1% decrease in RNAseq reads mapped (Fig. 2A, panel i). Further

increasing the mapping allowance from N5 to N10 had the opposite effect, with a greater number of

227 gene models having a decreased rather than an increased number of RNAseq reads mapped: A change

in the polymorphism allowance from N5 to N10 resulted in 12,529, 8,139, and 8,470 gene models

having a >1% decreased number of RNAseq reads mapped, compared with 1,092, 4,682 and 4,953
genes having an increased number of RNAseq reads mapped for MHco3(ISE), MHco4(WRS), and
MHco10(CAVR) strains respectively (Fig. 2A, panel ii).

232

3.2 The SNP allowance has a greater effect on RNAseq read mapping for gene models with higher
levels of sequence polymorphism.

235

236 There were large differences in the SNP rates of different gene models, relative to the 237 MHco3(ISE) reference genome, ranging from those with SNP rates of 0% to those above 5%. The 238 25,111 gene models were binned into several different SNP rate categories to investigate how the 239 mapping of RNAseq reads to the reference MHco3(ISE) genome assembly was affected by the coding 240 region SNP rate (Fig. 2B). The MHco4(WRS) and MHco10(CAVR) strains had a significantly greater 241 proportion of gene models with SNP rates greater than 0.5% [18,910 (75.3%) and 18,886 (75.2%) 242 respectively] compared with the MHco3(ISE) strain [11,303 (45.0%)] (Z-stat = 69.3 (p < 0.000) and 243 69.1 (p < 0.000 ) respectively) (Fig. 2B).

244 The effect of changing the polymorphism allowance from N2 to N5 on RNAseq read mapping 245 for each of the different SNP rate categories of gene models was examined for each strain (Fig. 2C, 246 panel i; Supplementary Table S1). The ratio of RNAseq reads mapping to gene models at the N5 247 compared to the N2 allowance was > 1 for all SNP rate categories above 0% for all three strains (Fig. 248 2C, panel i). Furthermore, this ratio increased as the SNP rate increased. In contrast, the ratio of 249 RNAseq reads mapping to gene models at the N10 allowance compared to the N5 allowance was < 1 250 except for gene models with a polymorphism frequency of > 5% for strains MHco4(WRS) and 251 MHco10(WRS) (Fig. 2C, panel ii).

3.3 High levels of sequence polymorphism artificially inflate between-strain RNAseq differential
 expression results.

255

256 We next investigated the influence of CDS sequence polymorphism on the RNAseq differential 257 expression reported by DESeq2 between pairwise strain comparisons. We hypothesized that gene 258 models with large differences in SNP rates (SNPs/bp) between two strains are more likely to be 259 reported as differentially expressed between those strains than gene models with smaller SNP rate 260 differences. To test this hypothesis, for each gene model we first determined the difference in SNP 261 rates (SNPs/bp) between each pairwise comparison of the three strains. We then plotted the difference 262 in the SNP rate between the two strains against the log2-fold difference in expression called by DESeq2 263 for each gene model (Fig. 3). Using the MHco4(WRS) and MHc03(ISE) pairwise comparison as an 264 example, for those gene models with a higher SNP rate in MHco4(WRS) than in MHco3(ISE), a 265 greater number was reported by *DESeq2* as down-regulated in MHco4(WRS) relative to MHco3(ISE) 266 than as up-regulated (Fig. 3A). This bias towards down-regulation increased as the SNP rate difference 267 of gene models between the two strains increased (Fig. 3A). For gene models with a lower SNP rate in 268 MHco4(WRS) than in MHco3(ISE), the opposite trend was apparent (Fig. 3B). Similar patterns were 269 observed in both the MHco3(ISE) vs. MHco10(CAVR) and MHco4(WRS) vs. MHco10(CAVR) 270 pairwise comparisons (Fig. 3C-F).

To further quantify how SNP rate differences between the strains biases reporting of differential expression, we placed each of the 25,049 gene models with SNP rate data into one of seven "SNP rate difference" categories for each pairwise strain comparison (data for the MHco3(ISE) vs. MHco4(WRS) pairwise comparison is shown in Figure 4, and Supplementary Table S2). The percentage of gene

275	models reported as differentially expressed (with adjusted p-values $< 0.05$ and $> \log 2.1X$ fold-change
276	in expression) was lowest for the $0\%$ SNP rate difference category and increased as the SNP rate
277	difference category increased (Fig. 4A). This trend was seen at all three SNP mapping allowances (Fig.
278	4A). There was also a strong relationship between the directionality of the differential expression called
279	by DESeq2 and the directionality of the SNP rate difference between the strains. For SNP rate
280	difference categories where the SNP rate was greater in MHco4(WRS) than in MHco3(ISE) by at least
281	2%, the large majority of gene models reported as differentially expressed were down-regulated in
282	MHco4(WRS) relative to MHco3(ISE) (396/425 (93.2%)) (Supplementary Table S2). Conversely, the
283	large majority of gene models with SNP rates at least 2% lower in MHco4(WRS) than in MHco3(ISE),
284	were up-regulated in MHco4(WRS) relative to MHco3(ISE) (21/27 (77.8%)) (Supplementary Table
285	S2).

286

287 3.4 Minimizing the effect of sequence polymorphism differences on differential expression analysis 288 in pairwise strain comparisons.

289

290 We next investigated ways to minimize the effect of sequence polymorphism on global transcriptomic differential expression analysis in pairwise strain comparisons. We first examined the 291 292 effect of changing the read mapping polymorphism allowance on the number and bias of the 293 differentially expressed genes reported by DESeq2 in pairwise strain comparisons. When the 294 polymorphism allowance was changed from N2 to N5 or from N5 to N10, there was an overall 295 decrease in the total number of differentially expressed genes reported in all three pairwise strain 296 comparisons (Supplementary Table S3). This trend was generally observed for genes in all SNP rate difference categories (see example of MHco3(ISE) vs. MHco4(WRS) pairwise comparison in Fig. 4A). 297

At the default N2 polymorphism allowance, *DESeq2* reported more genes down-regulated than upregulated in both MHco4(WRS) and MHco10(CAVR) when each was compared to MHco3(ISE) (Supplementary Fig. S1; Supplementary Table S3). This bias was reduced as the mapping allowance was increased to N5 and then N10 (Supplementary Fig. S1; Supplementary Table S3). In contrast, the MHco4(WRS) and MHco10(CAVR) pairwise comparison showed a relatively equal ratio of downregulated and up-regulated gene numbers even at the default N2 polymorphism allowance (Supplementary Fig. S1; Supplementary Table S3).

305 We then calculated the net (overall mean) differential expression (NDE) of all gene models in 306 each of the seven "SNP rate difference" categories for each of the pairwise strain comparisons to see if 307 there was an overall directional bias to the data (data for the MHco4(WRS) and MHco3(ISE) pairwise 308 strain comparison is shown in Fig. 4B). The NDE in the direction MHco4(WRS) > MHco3(ISE) was 309 greatest for those gene models in the 5 - 15% MHco4(WRS) > MHco3(ISE) SNP rate difference 310 category and least for gene models in the 0% SNP rate difference category (Fig. 4B, Supplementary 311 Table S2A). Conversely, the NDE in the direction MHco4(WRS) < MHco3(ISE) was highest for gene 312 models in the 5 - 15% MHco4(WRS) < MHco3(ISE) SNP rate difference category and least for the 0% 313 SNP rate difference category (Fig. 4B, Supplementary Table S2A). The NDE of gene models between 314 strains was highest at the N2 polymorphism mapping allowance, and least for the N10 polymorphism 315 mapping allowance, in all SNP rate difference categories (Fig. 4B; Supplementary Table S2A). 316 The NDE of gene models between the strains was relatively close to zero for genes of the three 317 lowest SNP rate difference categories, particularly at the N5 and N10 polymorphism allowances (Fig. 318 4B; Supplementary Table S2B). This suggests that gene models with < 2% difference in SNP rate 319 between strains had a minimal bias in pairwise strain differential expression analyses. We defined these analysis. These represent 17,881 out of the total of 25,111 gene models in the *H. contortus* whole
genome annotation (71.2%) and so represent the majority of gene models (Supplementary Fig. S2).

323

# 3.5 Investigating genuine transcriptional differences between H. contortus strains.

325

324

326 We restricted the global transcriptomic analysis to the low-polymorphic gene models, as defined 327 above, and used an N5 polymorphism allowance for read mapping to minimize the confounding 328 effect of inter-strain sequence polymorphism. This resulted in the inclusion of 20,781, 19,397, and 329 22,924 gene models for the MHco4(WRS) vs. MHco3(ISE), MHco10(CAVR) vs. MHco3(ISE), and 330 MHco4(WRS) vs. MHco10(CAVR) pairwise strain comparisons respectively (Supplementary Fig. S2). 331 A set of 17,881 genes was common to the analysis set for all three pairwise comparisons 332 (Supplementary Fig. S2). Normalized global expression of each of the nine bioreplicate RNAseq 333 datasets clustered by strain on PCA analysis demonstrating that there are transcriptomic differences 334 between the strains, even after the effects of sequence polymorphism on RNAseq mapping are 335 minimized (Supplementary Fig. S3). 336 A total of 1,125 (5.41% of LPGs), 1,498 (7.72% of LPGs), and 824 (3.59% of LPGs) genes were 337 differentially expressed at > 1X log2 fold in the MHco4(WRS) vs. MHco3(ISE), MHco10(CAVR) vs. 338 MHco3(ISE), and MHco4(WRS) vs. MHco10(CAVR) pairwise comparisons respectively (Fig. 5). Of 339 these, 134 genes (41 up-regulated, 93 down-regulated), 259 genes (121 up-regulated, 138 down 340 regulated), and 103 genes (40 up-regulated, 63 down regulated) were  $> 2X \log 2$  fold differentially 341 expressed respectively (Fig. 5). The large majority of the most differentially expressed genes in all 342 strains comparisons were either undescribed or had only broad ontological classifications 343 (Supplementary Table S4). No previously reported ivermectin resistance candidate low-polymorphic

genes were observed to be differentially expressed in at > 2X log2 fold-change expression in either of
the two ivermectin resistance strains relative to the MHCo3(ISE) susceptible strain (Supplementary
Table S4).

347 We examined the number of genes that were differentially expressed in more than one of the 348 pairwise strain comparisons to see if a set of genes was common to different pairwise comparisons. The 349 highest proportion of shared differentially expressed LPGs was between the MHco4(WRS) vs. 350 MHco3(ISE) and MHco10(CAVR) vs. MHco3(ISE) pairwise strain comparisons (Supplementary Fig. 351 S4). Of the 2,132 gene models differentially expressed between either MHco4(WRS) and 352 MHco10(CAVR) vs. MHco3(ISE), 491 (23.03%) were differentially expressed with the same 353 directionality (up- or down- regulated) in both pairwise comparisons at >1X log2 fold change (48 gene 354 models at  $> 2X \log 2$  fold change) (Supplementary Fig. S4A). Fewer genes were shared in the other two 355 strain combinations: of the 2,025 gene models differentially expressed between either MHco3(ISE) and 356 MHco4(WRS) strains vs. MHco10(CAVR), 297 (14.67%) gene models were differentially 357 expressed with the same directionality at >1 log2-fold change (39 gene models at >2 log2-fold 358 change) in both pairwise comparisons (Supplementary Fig. S4B). Of the 1,794 gene models 359 differentially expressed between either MHco3(ISE) and MHco10(CAVR) vs. MHco4(WRS), only 155 360 (8.64%) gene models were differentially expressed at >1 log2-fold change (8 gene models at >2 log2 361 fold change) with the same directionality in both comparisons (Supplementary Fig. S4C). Both these 362 percentages represent a significantly lower proportion of differentially expressed genes shared than were observed shared in MHco4(WRS) and MHco10(CAVR) vs. MHco3(ISE) (Z-stats =  $6.8 \text{ (p} < 10^{-1} \text{ (p}$ 363 364 0.000), and 12.1 (p < 0.000) respectively).

365

3.6 Investigating the effect of sequence polymorphism on differential expression analysis of two gene families of relevance to ivermectin resistance research.

368

367

369 67 ligand-gated chloride channels (LGICs) and 86 ABC transporters identified in the published H. 370 contortus draft genome (Laing et al, 2013) were examined for differential expression between the 371 MHco4(WRS) and MHco10(CAVR) ivermectin resistant strains and the susceptible MHco3(ISE) 372 strain. Three different differential expression analyses were compared to assess the impact of 373 accounting for sequence polymorphisms differences between the strains; using the default N2 SNP 374 allowance on all 25,111 gene models, using the N5 SNP allowance on all 25,111 genes, and using the 375 N5 SNP allowance on the set of 17,881 low-polymorphic genes (LPGs). There was a substantial 376 reduction in the total number of differentially expressed genes reported using the N5 allowance on the 377 LPG gene set compared with the N2 default allowance on the full gene set (Table 1). When comparing 378 the two ivermectin resistant strains with the ivermectin sensitive strain, only three of the low-379 polymorphic genes – *Hco-lgc-55*, *Hco-pmp-6*, and *Hco-lgc-44* – showed differential expression at the 380 N5 allowance in both the MHco4(WRS) and MHco10(CAVR) vs. MHco3(ISE) pairwise comparisons. 381 Hco-lgc-55 had > 2X log2 fold up-regulation in both cases (Table 1).

382

# 383 4. Discussion

384

Differential expression analysis, either at the single gene or whole transcriptome level, between parasitic nematode strains and isolates is a common experimental approach. For example, a number of candidate anthelmintic resistance genes have been identified by differential expression analysis of drug resistant and susceptible isolates (Dicker et al., 2011; El-Abdellati et al., 2011; Williamson et al., 2011; 389 Xu et al., 1998). In the case of *H. contortus*, we reasoned that the extremely high levels of sequence 390 polymorphism both within and between laboratory strains and field isolates (reviewed in Gilleard and 391 Redman, (2016)), might confound the validity of such comparisons when using RNAseq, which is now 392 the central approach to conducting differential gene expression analyses. The majority of researchers 393 use only the default parameters of RNAseq data analysis pipelines and do not explore the effect of 394 different parameters on results reported (Baruzzo et al., 2017). It has been shown, using simulated 395 datasets, that the parameter with the greatest impact on performance is the number of mismatches 396 tolerated by during read mapping (Baruzzo et al., 2017). Since this seemed likely to be a particular 397 issue for organisms with high levels of sequence polymorphism, we undertook a detailed analysis to 398 examine the extent to which this may impact RNAseq based differential expression analysis between 399 *H. contortus* strains, and investigate how it could be mitigated to allow genuine transcriptional 400 differences to be assessed. We used TopHat2 (Dobin and Gingeras, 2013) as our read mapping 401 software as this has been the mapping program most commonly used for RNAseq analysis over a 402 number of years and currently has the most citation in RNAseq literature. There are a number of 403 alternative mapping tools available whose use is becoming increasingly common, such as HISAT2 404 (Kim et al., 2015), which is *TopHat2*'s recommended successor, but these tools are similarly sensitive 405 to changes in the mismatch parameter (Baruzzo et al., 2017).

A higher percentage of RNAseq reads mapped to the reference genome assembly for MHco3(ISE) than for the MHco4(WRS) and MHco10(CAVR) strains (Fig. 1). This was hypothesized to be due to sequence polymorphism reducing read mapping efficiency and reflecting the higher overall CDS SNP rate in the latter two strains with respect to the MHco3(ISE) derived reference genome sequence (Fig. 1). This hypothesis was supported by the improvement of overall read mapping efficiency achieved by increasing SNP mapping allowance to N5 (allowing 5 SNPs and 3 indels per read) from the default N2 412 value (allowing 2 SNPs or 2 indels per read). This change in SNP mapping allowance resulted in an 413 increase in the number of reads mapped for a large number of gene models (Fig. 2A). This 414 improvement in read mapping efficiency, as a result of increased SNP mapping allowance, was not 415 confined to the MHco4(WRS) and MHco10(CAVR) data, but also occurred with the MHco3(ISE) data. 416 These results suggest that mapping efficiency is affected by both between-strain and within-strain 417 sequence polymorphism. We also investigated the extent to which sequence polymorphism varied 418 among gene models and how this affected read mapping efficiency (Fig. 2B). When SNP allowances 419 were increased from N2 to N5, genes with higher levels of polymorphism showed larger proportionate increases in reads mapped for all three strains (Fig. 2C, panel i). This further illustrates the impact of 420 421 sequence polymorphism on RNAseq read mapping efficiency and how it is greater for more 422 polymorphic genes.

423 Having shown that sequence polymorphism affects RNAseq read mapping to a reference genome 424 assembly with TopHat2, we next investigated how this might bias differential expression analysis using 425 DESeq2; one of the most commonly used bioinformatic tools for RNAseq data analysis (Fig. 3 and Fig. 426 4A). For each gene model, we plotted the DESeq2 differential expression results against the difference 427 in SNP rate (relative to the reference genome assembly) between the two strains being compared (Fig. 428 3). For each pairwise strain comparison, gene models which had higher differences in the level of 429 sequence polymorphism between the strains were more likely to be down-regulated than to be up-430 regulated in the strain with the highest level of sequence polymorphism (Fig. 3). Further, this bias 431 increased with the magnitude of difference in polymorphism rate of gene models between the strains 432 (Fig. 3 and Fig. 4A). This effect was true for all three pairwise strain comparisons, including between 433 the two "non-reference" MHco4(WRS) and MHco10(CAVR) strains. There is no obvious biological

reason for such differential expression biases, based on differences in SNP polymorphism rates, and so
we concluded this is due to the effect of sequence polymorphism on RNAseq mapping rates.

Consequently, biases due to inter-strain differences in SNP polymorphism rates needed to be 436 437 minimized before meaningful differential expression analysis could be performed. The first approach to 438 achieve this was to choose RNAseq read mapping parameters in *TopHat2* to maximize read mapping 439 efficiency for all the strains. Overall read mapping success peaked at the N5 or N6 SNP mapping 440 allowances, depending on the strain (with very little difference between these two values (Fig. 1)). At 441 the level of the gene model, the clear majority of genes had higher numbers of reads mapping at the N5 442 allowance than at either the N2 or N10 allowances (Fig. 2A). Consequently, the N5 mapping allowance 443 maximized read mapping efficiency. Furthermore, the directional biases in the differential expression 444 reports between strains were greatly reduced at the N5 mapping allowance (Fig. 4A-B, Supplementary 445 Fig. S1). Consequently, the N5 mapping allowance was considered optimal to use for further analysis. 446 However, optimizing the SNP mapping allowance did not completely remove the directional 447 expression biases. For example, even at the N5 SNP mapping allowance, although the directional expression bias was close to zero for genes with SNP rate difference between strains of < 2%, it 448 449 persisted for genes with a difference in SNP rate of > 2% (Fig. 4B). This led us to conclude that it was 450 not possible to reliably measure differential expression for those genes > 2% SNP rate differences 451 between strains, even at the N5 read mapping allowance. Consequently, we precluded these genes in 452 subsequent transcriptomic analysis. These results have important implications for differential 453 expression analysis between different strains/isolates of organisms with high levels of genetic diversity 454 and suggest that sequence polymorphism needs to be defined and accounted for as part of the analysis. 455 There are an number of other read mapping tools available for RNAseq analysis some of which, 456 although less widely used than *TopHat2*, may be less impacted by high levels of sequence

polymorphism (Baruzzo et al., 2017). *TopHat2* is still widely used but it is noteworthy that the mapping tool which is increasingly used in place *TopHat2* is *HISAT2*, which is only slightly less sensitive to changes in mismatch parameters using simulated datasets (Baruzzo et al., 2017). Other read mapping tools such as *NovoAlign* (http://www.novocraft.com/products/novoalign/) or *GSNAP* (Wu and Nacu, 2010), that may be less impacted by sequence polymorphism, deserve more exploration for use in RNAseq differential expression pipelines for organisms such as *H. contortus* with high levels of genetic variation.

464 Pairwise comparisons of three genetically divergent strains of *H. contortus* revealed large numbers 465 of differentially expressed genes, even after the confounding effects of sequence polymorphism were 466 removed (Fig. 5). The proportion of differentially expressed genes between the H. contortus strains far exceed those previously observed in inter-population studies of vertebrate species such as human and 467 468 mouse (Bottomly et al., 2011; Li et al., 2014), and it is greater than has been reported between different 469 strains of C. elegans (N2/Bristol and CB4856/Hawaiian strains) (Capra et al., 2008; Francesconi and 470 Lehner, 2014). This remarkably large number of differentially expressed genes between these H. 471 contortus strains may have many different phenotypic traits which could have a variety of implications 472 for their life history traits, epidemiology, pathogenicity, and susceptibility to drugs and/or vaccines. 473 This reflects the high genetic diversity of *H. contortus* and of these particular strains. MHco3(ISE), 474 MHco4(WRS), and MHco10(CAVR) are derived from field isolates obtained from different continents 475 and are highly genetically divergent (Gilleard and Redman, 2016; Redman et al., 2012, 2008). For 476 example, the levels of genetic diversity (Fst values) between strains based on microsatellite genotyping 477 ranged from 0.1530 to 0.2696 which is as high or higher than some closely related species in some 478 cases (Prado-Martinez et al., 2013; Redman et al., 2008; Romiguier et al., 2014). Further, although the 479 nematode body plan is superficially simple, a variety of morphological and morphometric traits vary

between these three strains, including vulval morphology, oesophagus length, and spicule length in
males as well as the extent of the synlophe cuticular ridges in females (Gilleard and Redman, 2016;
Sargison et al., 2019). Also, there is evidence of lethality of some hybrid progeny of these strains
(Sargison et al., 2019).

484 The results of this study also have important implications for anthelmintic resistance research 485 which, until very recently, has been dominated by candidate gene studies (Gilleard, 2013, 2006; 486 Rezansoff et al., 2016). In the case of ivermectin resistance, such studies have so far failed to identify 487 the key loci or genes involved in resistance for any parasitic nematode, including H. contortus 488 (Gilleard, 2013). One common component of candidate gene studies has been to compare the 489 expression levels of specific candidate genes between a small number of ivermectin resistant and 490 susceptible parasite strains (Dicker et al., 2011; El-Abdellati et al., 2011; Williamson et al., 2011; Xu et 491 al., 1998). It is common for such studies to report differences in expression between resistant and 492 susceptible strains for candidate genes such as P-glycoproteins (PGPs) or ligand-gated ion channels 493 (LGICs). These differences are commonly used as circumstantial evidence for a role in resistance. Our 494 results here show the context in which such studies should be interpreted as a very large number of 495 genes are differentially expressed in pairwise comparisons of genetically divergent H. contortus strains 496 (Fig. 5). 824 - 1,498 low-polymorphic genes were differentially expressed between the strains in the 497 study at a level of 2-fold and an adjusted statistical significance of p < 0.05 (as called by *DESeq2*). This 498 highlights the inherently high levels of "background" transcriptomic variation that occur between 499 genetically divergent *H. contortus* strains. Consequently, care must be taken when interpreting a 500 suggested association of differential expression of a gene with a drug resistance phenotype when a 501 small number of genes are compared between a small number of drug resistant and susceptible strains.

This is particularly the case when the degree of genetic differentiation or the general level oftranscriptomic difference that exists between the strains has not been assessed.

504 Recently, studies analyzing the expression of small numbers of candidate genes are being replaced 505 with more global transcriptomic studies. The draft H. contortus genome and its recent improvement 506 into a chromosomal level assembly is making such studies increasingly feasible on a genome-wide 507 scale (Doyle et al., 2018; Laing et al., 2013). The work presented here also has important implications 508 for global transcriptomic comparisons of drug resistant and susceptible strains. Two gene families often 509 suggested to be involved in ivermectin resistance are the LGICs and ABC transporter genes (Laing et 510 al., 2013). We used the gene models in the H. contortus draft annotation to assess how many members 511 of these gene families were differentially expressed between the MHco4(WRS) and MHco10(CAVR) 512 ivermectin resistant strains and the MHco3(ISE) susceptible strain using the default polymorphism allowance (N2), the optimized polymorphism allowance (N5), and the polymorphism allowance (N5) 513 514 but removing the highly polymorphic gene set (Table 1). We found there was a dramatic reduction in 515 the number of members of these genes families that were determined to be differentially expressed 516 when polymorphism allowance was increased to the optimal N5 allowance (Table 1). A further 517 reduction was apparent when the most highly polymorphic genes were discarded from the analysis 518 (Table 1).

These results highlight the fact that a substantial number of differentially expressed genes reported are likely to be artifacts caused by differences in sequence polymorphism between the strains being compared which are not accounted for. In the case of our analysis, accounting for sequence polymorphism reveals a smaller number of differentially expressed candidate genes perhaps worthy of further investigation. The ABC transporter *Hco-pmp-6*, and two LGICs – *Hco-lgc-55* and *Hco-lgc-44* – were differentially expressed with the same directionality in both ivermectin resistant strains relative to

525	the MHco3(ISE) strain. <i>Hco-lgc-55</i> is a tyramine-gated chloride channel whose <i>C. elegans</i> homologue
526	Cel-lgc-55 is expressed in the pharynx and is involved in worm motility (Rao et al., 2010; Ringstad et
527	al., 2009). The ABC transporter Hco-wht-4, and the LGICs Hco-lgc-3, Hco-lgc-33, Hco-lgc-9, and
528	<i>Hco-acr-24</i> were other genes with a $> 2X \log 2$ fold-change differential expression in the
529	MHco10(CAVR) strain, although these genes were not differentially expressed in the other resistant
530	strain, MHco4(WRS). <i>Hco-lgc-3</i> was the gene with the highest level of up-regulation across both these
531	gene families, being differentially expressed at greater than 50-fold in MHco3(CAVR) relative to
532	MHco3(ISE) (Table 1). The gene may be considered of interest given its homology to a paralogous pair
533	of C. elegans proton-gated ion channels, Cel-pbo-5 and Cel-pbo-6, which are required for normal
534	posterior muscle function (Beg et al., 2008). However, further functional and genetic studies are
535	required before making any inferences of the potential role of these genes in mediating the ivermectin
536	resistance phenotype of <i>H. contortus</i> .

. .

\_ \_ .

537

# 538 Acknowledgements

We are grateful to Dr Matt Workentine for comments on the manuscript. We are grateful for funding from NSERC Discovery Grant, NSERC-CREATE Host-Parasites Interactions (HPI) program and the Biotechnology and Biological Sciences Research Council (BBSRC). The Moredun Research Institute (DJB and AAM) receives funding from the Scottish Government. NS was funded from the Higher Education Funding Council of England (HEFCE), the Department for Environment, Food and Rural Affairs (DEFRA) and the Scottish Funding Council (SFC) Veterinary Training Research Initiative (VTRI) programme VT0102 and for the support of Pfizer Animal Health.

546

# 547 **References**

- Anders, S., Pyl, P.T., Huber, W., 2014. HTSeq A Python framework to work with high-throughput
   sequencing data HTSeq A Python framework to work with high-throughput sequencing data.
   Bioinformatics. 31, 0–5. https://doi.org/10.1093/bioinformatics/btu638
- 551 Andersen, E.C., Gerke, J.P., Shapiro, J.A., Crissman, J.R., Ghosh, R., Bloom, J.S., Felix, M.-A.,
- 552 Kruglyak, L., 2012. Chromosome-scale selective sweeps shape Caenorhabditis elegans genomic

- 553 diversity. Nat. Genet. 44, 285–295. https://doi.org/10.1038/ng.1050
- Antony, H.A., Pathak, V., Parija, S.C., Ghosh, K., Bhattacherjee, A., 2016. Transcriptomic Analysis of
   Chloroquine-Sensitive and Chloroquine-Resistant Strains of Plasmodium falciparum : Toward
   Malaria Diagnostics and Therapeutics for Global Health. Omi. A J. Integr. Biol. 20, 424–432.
   https://doi.org/10.1089/omi.2016.0058
- Baruzzo, G., Hayer, K.E., Kim, E.J., DI Camillo, B., Fitzgerald, G.A., Grant, G.R., 2017. Simulationbased comprehensive benchmarking of RNA-seq aligners. Nat. Methods 14, 135–139.
  https://doi.org/10.1038/nmeth.4106
- 561 Bateman, A., Martin, M.J., O'Donovan, C., Magrane, M., Apweiler, R., Alpi, E., Antunes, R.,
- 562 Arganiska, J., Bely, B., Bingley, M., Bonilla, C., Britto, R., Bursteinas, B., Chavali, G., Cibrian-
- 563 Uhalte, E., Da Silva, A., De Giorgi, M., Dogan, T., Fazzini, F., Gane, P., Castro, L.G., Garmiri, P.,
- 564 Hatton-Ellis, E., Hieta, R., Huntley, R., Legge, D., Liu, W., Luo, J., Macdougall, A., Mutowo, P.,
- 565 Nightingale, A., Orchard, S., Pichler, K., Poggioli, D., Pundir, S., Pureza, L., Qi, G., Rosanoff, S.,
- 566 Saidi, R., Sawford, T., Shypitsyna, A., Turner, E., Volynkin, V., Wardell, T., Watkins, X., Zellner,
- 567 H., Cowley, A., Figueira, L., Li, W., McWilliam, H., Lopez, R., Xenarios, I., Bougueleret, L.,
- 568 Bridge, A., Poux, S., Redaschi, N., Aimo, L., Argoud-Puy, G., Auchincloss, A., Axelsen, K.,
- 569 Bansal, P., Baratin, D., Blatter, M.C., Boeckmann, B., Bolleman, J., Boutet, E., Breuza, L., Casal-
- Casas, C., De Castro, E., Coudert, E., Cuche, B., Doche, M., Dornevil, D., Duvaud, S., Estreicher,
  A., Famiglietti, L., Feuermann, M., Gasteiger, E., Gehant, S., Gerritsen, V., Gos, A., Gruaz-
- A., Famiglietti, L., Feuermann, M., Gasteiger, E., Gehant, S., Gerritsen, V., Gos, A., GruazGumowski, N., Hinz, U., Hulo, C., Jungo, F., Keller, G., Lara, V., Lemercier, P., Lieberherr, D.,
- 573 Lombardot, T., Martin, X., Masson, P., Morgat, A., Neto, T., Nouspikel, N., Paesano, S.,
- 574 Pedruzzi, I., Pilbout, S., Pozzato, M., Pruess, M., Rivoire, C., Roechert, B., Schneider, M., Sigrist,
- 575 C., Sonesson, K., Staehli, S., Stutz, A., Sundaram, S., Tognolli, M., Verbregue, L., Veuthey, A.L.,
- 576 Wu, C.H., Arighi, C.N., Arminski, L., Chen, C., Chen, Y., Garavelli, J.S., Huang, H., Laiho, K.,
- 577 McGarvey, P., Natale, D.A., Suzek, B.E., Vinayaka, C.R., Wang, Q., Wang, Y., Yeh, L.S.,
- 578 Yerramalla, M.S., Zhang, J., 2015. UniProt: A hub for protein information. Nucleic Acids Res. 43,
  579 D204–D212. https://doi.org/10.1093/nar/gku989
- Beg, A.A., Ernstrom, G.G., Nix, P., Davis, M.W., Jorgensen, E.M., 2008. Protons Act as a Transmitter
  for Muscle Contraction in C. elegans. Cell 132, 149–160.
- 582 https://doi.org/10.1016/j.cell.2007.10.058
- Blumenthal, T., Davis, R.E., 2004. Exploring nematode diversity. Nat. Genet.
   https://doi.org/10.1038/ng1204-1246
- Bottomly, D., Walter, N.A.R., Hunter, J.E., Darakjian, P., Kawane, S., Buck, K.J., Searles, R.P.,
  Mooney, M., McWeeney, S.K., Hitzemann, R., 2011. Evaluating gene expression in C57BL/6J
  and DBA/2J mouse striatum using RNA-Seq and microarrays. PLoS One 6.
  https://doi.org/10.1371/journal.pone.0017820
- Capra, E.J., Skrovanek, S.M., Kruglyak, L., 2008. Comparative developmental expression profiling of
   two C. elegans isolates. PLoS One 3. https://doi.org/10.1371/journal.pone.0004055
- 591 Cingolani, P., Platts, A., Wang, L.L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., Ruden,
   592 D.M., 2012. A program for annotating and predicting the effects of single nucleotide
   593 polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain. Fly (Austin). 6,
   594 80–92. https://doi.org/10.4161/fly.19695
- 595 Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A., Szcześniak,
  596 M.W., Gaffney, D.J., Elo, L.L., Zhang, X., Mortazavi, A., 2016. A survey of best practices for
  597 RNA-seq data analysis. Genome Biol. https://doi.org/10.1186/s13059-016-0881-8
- 598 Croken, M.M.K., Ma, Y., Markillie, L.M., Taylor, R.C., Orr, G., Weiss, L.M., Kim, K., 2014. Distinct

- strains of Toxoplasma gondii feature divergent transcriptomes regardless of developmental stage.
   PLoS One 9, 1–10. https://doi.org/10.1371/journal.pone.0111297
- 601 Dey, A., Chan, C.K.W., Thomas, C.G., Cutter, A.D., 2013. Molecular hyperdiversity defines
   602 populations of the nematode Caenorhabditis brenneri. Proc. Natl. Acad. Sci. 110, 11056–11060.
   603 https://doi.org/10.1073/pnas.1303057110
- Dicker, A.J., Nisbet, A.J., Skuce, P.J., 2011. Gene expression changes in a P-glycoprotein (Tci-pgp-9)
   putatively associated with ivermectin resistance in Teladorsagia circumcincta. Int. J. Parasitol. 41,
   935–942. https://doi.org/10.1016/j.ijpara.2011.03.015
- Dobin, A., Gingeras, T.R., 2013. Comment on "TopHat2: accurate alignment of transcriptomes in the
   presence of insertions, deletions and gene fusions" by Kim et al. 2013. bioRxiv 0–9.
   https://doi.org/10.1101/000851
- Doyle, S.R., Illingworth, C.J.R., Laing, R., Bartley, D.J., Redman, E., Martinelli, A., Holroyd, N.,
  Morrison, A.A., Rezansoff, A., Tracey, A., Devaney, E., Berriman, M., Sargison, N., Cotton, J.A.,
  Gilleard, J.S., 2019. Population genomic and evolutionary modelling analyses reveal a single
  major QTL for ivermectin drug resistance in the pathogenic nematode, Haemonchus contortus.
  BMC Genomics 20, 218. https://doi.org/10.1186/s12864-019-5592-6
- Doyle, S.R., Laing, R., Bartley, D.J., Britton, C., Chaudhry, U., Gilleard, J.S., Holroyd, N., Mable,
  B.K., Maitland, K., Morrison, A.A., Tait, A., Tracey, A., Berriman, M., Devaney, E., Cotton, J.A.,
  Sargison, N.D., 2018. A Genome Resequencing-Based Genetic Map Reveals the Recombination
  Landscape of an Outbred Parasitic Nematode in the Presence of Polyploidy and Polyandry.
  Genome Biol. Evol. 10, 396–409. https://doi.org/10.1093/gbe/evx269
- Edwards, J.A., Chen, C., Kemski, M.M., Hu, J., Mitchell, T.K., Rappleye, C.A., 2013. Histoplasma
   yeast and mycelial transcriptomes reveal pathogenic-phase and lineage-specific gene expression
   profiles. BMC Genomics 14, 695. https://doi.org/10.1186/1471-2164-14-695
- El-Abdellati, A., De Graef, J., Van Zeveren, A., Donnan, A., Skuce, P., Walsh, T., Wolstenholme, A.,
  Tait, A., Vercruysse, J., Claerebout, E., Geldhof, P., 2011. Altered avr-14B gene transcription
  patterns in ivermectin-resistant isolates of the cattle parasites, Cooperia oncophora and Ostertagia
  ostertagi. Int. J. Parasitol. 41, 951–957. https://doi.org/10.1016/j.ijpara.2011.04.003
- Fiebig, M., Kelly, S., Gluenz, E., 2015. Comparative Life Cycle Transcriptomics Revises Leishmania
   mexicana Genome Annotation and Links a Chromosome Duplication with Parasitism of
   Vertebrates. PLoS Pathog. 11, 1–28. https://doi.org/10.1371/journal.ppat.1005186
- Francesconi, M., Lehner, B., 2014. The effects of genetic variation on gene expression dynamics
   during development. Nature 505, 208–211. https://doi.org/10.1038/nature12772
- Gilleard, J.S., 2013. Haemonchus contortus as a paradigm and model to study anthelmintic drug
   resistance. Parasitology 140, 1506–1522. https://doi.org/10.1017/S0031182013001145
- Gilleard, J.S., 2006. Understanding anthelmintic resistance: The need for genomics and genetics. Int. J.
   Parasitol. https://doi.org/10.1016/j.ijpara.2006.06.010
- Gilleard, J.S., Redman, E., 2016. Genetic Diversity and Population Structure of Haemonchus contortus,
   in: Advances in Parasitology. pp. 31–68. https://doi.org/10.1016/bs.apar.2016.02.009
- Guryev, V., Koudijs, M.J., Berezikov, E., Johnson, S.L., Plasterk, R.H.A., van Eeden, F.J.M., Cuppen,
  E., 2006. Genetic variation in the zebrafish. Genome Res. 16, 491–7.
  https://doi.org/10.1101/gr.4791006
- Kim, D., Langmead, B., Salzberg, S.L., 2015. HISAT: a fast spliced aligner with low memory
   requirements. Nat. Methods 12, 357–360. https://doi.org/10.1038/nmeth.3317
- Laing, R., Hunt, M., Protasio, A. V, Saunders, G., Mungall, K., Laing, S., Jackson, F., Quail, M.,
- Beech, R., Berriman, M., Gilleard, J.S., 2011. Annotation of two large contiguous regions from

- the Haemonchus contortus genome using RNA-seq and comparative analysis with Caenorhabditis
  elegans. PLoS One 6, e23216. https://doi.org/10.1371/journal.pone.0023216
- Laing, R., Kikuchi, T., Martinelli, A., Tsai, I., Beech, R., Redman, E., Holroyd, N., Bartley, D.,
- 648 Beasley, H., Britton, C., Curran, D., Devaney, E., Gilabert, A., Hunt, M., Jackson, F., Johnston, S.,
- Kryukov, I., Li, K., Morrison, A., Reid, A., Sargison, N., Saunders, G., Wasmuth, J.,
  Wolstenholme, A., Berriman, M., Gilleard, J., Cotton, J., 2013. The genome and transcriptome of
- Haemonchus contortus, a key model parasite for drug and vaccine discovery. Genome Biol. 14,
   R88. https://doi.org/10.1186/gb-2013-14-8-r88
- Le Jambre, L., Gill, J., Lenane, I., Lacey, E., 1995. Characterization of an avermectin resistant strain of
   autralian Haemonchus contortus. Int. J. Parasitol. 25, 691–698.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin,
  R., Subgroup, 1000 Genome Project Data Processing, 2009. The Sequence Alignment/Map format
  and SAMtools. Bioinformatics 25, 2078–2079. https://doi.org/10.1093/bioinformatics/btp352
- Li, J., Lai, K., Ching, A.K.K., Chan, T., 2014. Genomics Transcriptome sequencing of Chinese and
  Caucasian population identi fi es ethnic-associated differential transcript abundance of
  heterogeneous nuclear ribonucleoprotein K (hnRNPK). Genomics 103, 56–64.
  https://doi.org/10.1016/j.ugene.2013.12.005
- 661 https://doi.org/10.1016/j.ygeno.2013.12.005
- Lindblad-Toh, K., Lander, E.S., Winchester, E., Daly, M.J., Wang, D.G., Hirschhorn, J.N., Laviolette,
  J.-P., Ardlie, K., Reich, D.E., Robinson, E., Sklar, P., Shah, N., Thomas, D., Fan, J.-B., Gingeras,
  T., Warrington, J., Patil, N., Hudson, T.J., 2000. Large-scale discovery and genotyping of singlenucleotide polymorphisms the mouse. Nat. Genet. 24, 381–386. https://doi.org/10.1038/74215
- Love, M.I., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion for
   RNA-seq data with DESeq2. Genome Biol. 15, 1–21. https://doi.org/10.1186/s13059-014-0550-8
- Papenfort, K., Förstner, K.U., Cong, J., Sharma, C.M., Bassler, B.L., 2015. Differential RNA-seq of
   Vibrio cholerae identifies the VqmR small RNA as a regulator of biofilm formation. Proc. Natl.
   Acad. Sci. 112, E766–E775. https://doi.org/10.1073/pnas.1500203112
- Pathan, M., Keerthikumar, S., Ang, C.S., Gangoda, L., Quek, C.Y.J., Williamson, N.A., Mouradov, D.,
  Sieber, O.M., Simpson, R.J., Salim, A., Bacic, A., Hill, A.F., Stroud, D.A., Ryan, M.T., Agbinya,
  J.I., Mariadason, J.M., Burgess, A.W., Mathivanan, S., 2015. FunRich: An open access standalone
  functional enrichment and interaction network analysis tool. Proteomics 15, 2597–2601.
  https://doi.org/10.1002/pmic.201400515
- 676 Prado-Martinez, J., Sudmant, P.H., Kidd, J.M., Li, H., Kelley, J.L., Lorente-Galdos, B., Veeramah,
- 677 K.R., Woerner, A.E., O'Connor, T.D., Santpere, G., Cagan, A., Theunert, C., Casals, F.,
- Laayouni, H., Munch, K., Hobolth, A., Halager, A.E., Malig, M., Hernandez-Rodriguez, J.,
- 679 Hernando-Herraez, I., Prüfer, K., Pybus, M., Johnstone, L., Lachmann, M., Alkan, C., Twigg, D.,
- 680 Petit, N., Baker, C., Hormozdiari, F., Fernandez-Callejo, M., Dabad, M., Wilson, M.L., Stevison,
- 681 L., Camprubí, C., Carvalho, T., Ruiz-Herrera, A., Vives, L., Mele, M., Abello, T., Kondova, I.,
- Bontrop, R.E., Pusey, A., Lankester, F., Kiyang, J.A., Bergl, R.A., Lonsdorf, E., Myers, S.,
- Ventura, M., Gagneux, P., Comas, D., Siegismund, H., Blanc, J., Agueda-Calpena, L., Gut, M.,
  Fulton, L., Tishkoff, S.A., Mullikin, J.C., Wilson, R.K., Gut, I.G., Gonder, M.K., Ryder, O.A.,
- Fulton, L., Tishkoff, S.A., Mullikin, J.C., Wilson, R.K., Gut, I.G., Gonder, M.K., Ryder, O.A.,
  Hahn, B.H., Navarro, A., Akey, J.M., Bertranpetit, J., Reich, D., Mailund, T., Schierup, M.H.,
- 686 Hvilsom, C., Andrés, A.M., Wall, J.D., Bustamante, C.D., Hammer, M.F., Eichler, E.E., Marques-
- 687 Bonet, T., 2013. Great ape genetic diversity and population history. Nature 499, 471–475.
- 688 https://doi.org/10.1038/nature12228
- Rao, V.T.S., Accardi, M. V., Siddiqui, S.Z., Beech, R.N., Prichard, R.K., Forrester, S.G., 2010.
- 690 Characterization of a novel tyramine-gated chloride channel from Haemonchus contortus. Mol.

691 Biochem. Parasitol. 173, 64–68. https://doi.org/10.1016/j.molbiopara.2010.05.005

- Redman, E., Packard, E., Grillo, V., Smith, J., Jackson, F., Gilleard, J.S., 2008. Microsatellite analysis
   reveals marked genetic differentiation between Haemonchus contortus laboratory isolates and
   provides a rapid system of genetic fingerprinting. Int. J. Parasitol. 38, 111–22.
- 695 https://doi.org/10.1016/j.ijpara.2007.06.008
- Redman, E., Sargison, N., Whitelaw, F., Jackson, F., Morrison, A., Bartley, D.J., Gilleard, J.S., 2012.
   Introgression of Ivermectin Resistance Genes into a Susceptible Haemonchus contortus Strain by Multiple Backcrossing. PLoS Pathog. 8, e1002534. https://doi.org/10.1371/journal.ppat.1002534
- Redman, E., Whitelaw, F., Tait, A., Burgess, C., Bartley, Y., Skuce, P.J., Jackson, F., Gilleard, J.S.,
  2015. The emergence of resistance to the benzimidazole anthlemintics in parasitic nematodes of
  livestock is characterised by multiple independent hard and soft selective sweeps. PLoS Negl.
  Trop. Dis. 9, e0003494. https://doi.org/10.1371/journal.pntd.0003494
- Rezansoff, A.M., Laing, R., Gilleard, J.S., 2016. Evidence from two independent backcross
  experiments supports genetic linkage of microsatellite Hcms8a20, but not other candidate loci, to
  a major ivermectin resistance locus in Haemonchus contortus. Int. J. Parasitol. 46, 653–661.
  https://doi.org/10.1016/j.ijpara.2016.04.007
- Ringstad, N., Abe, N., Horvitz, H.R., 2009. Ligand-gated chloride channels are receptors for biogenic
   amines in C. elegans. Science 325, 96–100. https://doi.org/10.1126/science.1169243
- Romiguier, J., Gayral, P., Ballenghien, M., Bernard, A., Cahais, V., Chenuil, A., Chiari, Y., Dernat, R.,
  Duret, L., Faivre, N., Loire, E., Lourenco, J.M., Nabholz, B., Roux, C., Tsagkogeorga, G., Weber,
  A.A.T., Weinert, L.A., Belkhir, K., Bierne, N., Glémin, S., Galtier, N., 2014. Comparative
  population genomics in animals uncovers the determinants of genetic diversity. Nature 515, 261–
  263. https://doi.org/10.1038/nature13685
- Sargison, N.D., Redman, E., Morrison, A.A., Bartley, D.J., Jackson, F., Hoberg, E., Gilleard, J.S.,
   2019. Mating barriers between genetically divergent strains of the parasitic nematode
   Haemonchus contortus suggest incipient speciation. Int. J. Parasitol.
- 717 https://doi.org/10.1016/j.ijpara.2019.02.008
- Urdaneta-Marquez, L., Bae, S.H., Janukavicius, P., Beech, R., Dent, J., Prichard, R., 2014. A dyf-7
  haplotype causes sensory neuron defects and is associated with macrocyclic lactone resistance
  worldwide in the nematode parasite Haemonchus contortus. Int. J. Parasitol. 44, 1063–1071.
  https://doi.org/10.1016/j.ijpara.2014.08.005
- Van Wyk, J.A., Malan, F.S., 1988. Resistance of field strains of Haemonchus contortus to ivermectin,
  closantel, rafoxanide and the benzimidazoles in South Africa. Vet. Rec. 123, 226–228.
  https://doi.org/10.1136/vr.123.9.226
- Wang, D.G., 1998. Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide
   Polymorphisms in the Human Genome. Science (80-. ). 280, 1077–1082.
   https://doi.org/10.1126/science.280.5366.1077
- Wang, Z., Gerstein, M., Snyder, M., 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat.
   Rev. Genet. 10, 57–63. https://doi.org/10.1038/nrg2484
- Williamson, S.M., Storey, B., Howell, S., Harper, K.M., Kaplan, R.M., Wolstenholme, A.J., 2011.
  Candidate anthelmintic resistance-associated gene expression and sequence polymorphisms in a
  triple-resistant field isolate of Haemonchus contortus. Mol. Biochem. Parasitol. 180, 99–105.
  https://doi.org/10.1016/j.molbiopara.2011.09.003
- Wu, T.D., Nacu, S., 2010. Fast and SNP-tolerant detection of complex variants and splicing in short
   reads. Bioinformatics 26, 873–881. https://doi.org/10.1093/bioinformatics/btq057
- 736 Xu, M., Molento, M., Blackhall, W., Ribeiro, P., Beech, R., Prichard, R., 1998. Ivermectin resistance in

737 738

739

nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol. 91, 327–335. https://doi.org/10.1016/S0166-6851(97)00215-6

- 740 Figure Legends
- 741

Figure 1. The percentage of RNAseq reads that mapped to the MHco3(ISE) reference genome
assembly at different *TopHat2* SNP (polymorphism) allowances (N2 to N10) shown for each of the
three *H. contortus* strains MHco3(ISE), MHco4(WRS), and MHco10(CAVR).

745

Figure 2. A) The number of genes which had either a >1% increase (green bars) or >1% decrease (red bars) in the number of RNAseq reads mapping to them on the reference MHco3(ISE) genome assembly following an increase in the read mapping polymorphism allowance in *TopHat2* for *H. contortus* strains MHco3(ISE), MHco4(WRS), and MHco10(CAVR). Panel *i* shows the data for a change in

polymorphism allowance of N2 to N5 and panel *ii* shows the data for a change from N5 to N10. B) The number of gene models in each SNP rate category for each *H. contortus* strain. The SNP rate for each gene model was calculated by dividing the number of SNPs in each CDS by the total CDS length for each gene model. C) Ratios of the total number of RNAseq reads mapping to gene models in each SNP rate category at two different SNP mapping allowances for each *H. contortus* strain. Panel *i* shows the N5:N2 ratio. Panel *ii* shows the N10:N5 ratio. Counts of reads mapped were totaled for all genes within

- each SNP rate category of each strain (colour coded).
- 757

758 Figure 3. Scatter plots of the differential expression of gene models, as determined by DESeq2 (X-759 axis), plotted against their difference in SNP rate percentage between the two strains being compared 760 (Y-axis). Gene model data points in each pairwise comparison are split into two panels, the left panel 761 showing the gene models with higher SNP rates in one strain of each pairwise comparison and the right 762 panel showing the gene models with higher SNP rates in the other pairwise strain. A and B show the 763 MHco4(WRS) vs. MHco3(ISE) comparison, C and D show the MHco10(CAVR) vs. MHco3(ISE) 764 comparison, and E and F show the MHco4(WRS) vs. MHco10(CAVR) comparison. The difference in 765 the SNP rate percentage between the two strains is shown on the y-axis and plotted against reported 766 log2 fold-change differential expression for each gene. The red lines represent zero differential 767 expression.

768

Figure 4. A) The percentage of expressed gene models in each SNP rate difference category that are
differentially expressed between MHco3(ISE) and MHco4(WRS) (log2 fold-change > 1X; adjusted pvalue < 0.05) for each of the three SNP (polymorphism) allowances – N2, N5, and N10 – when</li>
mapping. B) The net log2 fold differences in expression (NDE) of all expressed genes in each SNP rate
difference category. NDEs are shown for the N2, N5 and N10 SNP allowances when read mapping for
the MHco3(ISE) vs. MHco4(WRS) pairwise comparison. NDEs are the mean value for all genes in
each SNP rate difference category. Negative NDE values indicate an overall bias towards down-

regulation of genes in MHco4(WRS) vs. MHco3(ISE) strain. Positive values report an overall bias
 towards up-regulation of genes.

778

Figure 5. The total number of differentially expressed low-polymorphic genes (LPGs) observed in each
pairwise strain comparison at the N5 mapping allowance. Gene counts at both > 1X log2 fold-change
(orange dots), and > 2X log2 fold-change (red dots) thresholds are shown. The blue line on the y-axis
represents an adjusted p-value of 0.05.

783 784

786 787

788 789

790

791

792

793

794

795

#### 785 Supplementary Figure Legends

**Supplementary Figure S1**. Volcano plots showing differential expression of gene models at three different SNP allowances in *Tophap2's* mapping parameters (N2, N5, N10) are shown for each pairwise strain comparison. Log2 fold-change difference in expression from -4 to 4 is represented along the x-axis of each chart, and *DESeq2* -log10 adjusted p-values of the differential expression calls from 0 to 30 are represented along the y-axis. Gene positions exceeding a maximum value on either axis are placed at max value on that axis. Red points on the right and left sides of each plot represent genes differentially expressed at > 1X and < -1X log2 fold-change respectively with adjusted p-values < 0.05. Blue points represent genes significantly differentially expressed but at less than 1X log2 fold-change in either direction.

796

**Supplementary Figure S2**. Venn diagram showing the numbers of gene models qualifying as lowpolymorphic genes to be included in the different pairwise strain comparisons. The total number of genes qualifying as low-polymorphic genes in each of the pairwise strain comparisons are shown outside respective circles (i.e. gene models with differences in SNP rates between the two strains of < 2%). The number of these genes shared and not shared among the pairwise strain comparisons are shown within respective Venn circles.

803

804 **Supplementary Figure S3**. A PCA plot representing the variance in log gene expression of low-805 polymorphic genes of each triplicate dataset for each of the three populations when mapped at the N5 806 mapping allowance.

807

808 **Supplementary Figure S4**. Venn diagrams showing the numbers of genes differentially expressed in 809 each pairwise strain comparison, and shared differentially expressed between different pairwise strain 810 comparisons. Venn circles are colour coded by pairwise strain comparison – red represents 811 differentially expressed gene numbers of the MHco4(WRS) vs. MHco3(ISE) comparison, orange 812 represents the MHco10(CAVR) vs. MHco3(ISE) comparison, and green represents the MHco4(WRS) 813 vs. MHco10(CAVR) comparison. Differentially expressed genes were counted and cross-referenced at

- 814 two thresholds of differential expression: log2 fold-change difference in expression > 1 (italicized), and
- 815 log2 fold-change difference in expression > 2 (bolded).

-
മ
σ
1
Ψ.
-
~
Q
_
-

### Tables.

SNP rate between the two strains compared. SNP allowance with the highly polymorphic genes removed (right column). Highly polymorphic genes comprise genes with a > 2% difference in genes differentially expressed at the default (N2) SNP allowance are shown (left column), at the N5 SNP allowance (middle column), and at the N5 MHco4(WRS) (A and C) and MHco10(CAVR) (B and D) relative to the ivermectin susceptible reference strain – MHco3(ISE). In each panel, all transporters (C and D). The respective log2 fold-change differences in expression are shown for both of the ivermectin resistant strains -Table 1. Differentially expressed genes of ivermectin resistance candidate gene families, the ligand-gated ion channels (LGICs) (A and B), and ABC

Hco-lgc-27 -1.12 Hco-lgc-40 -1.07	-1.29 -1.18	-1.5		<i>Нсо-асг-17b</i> -1.78	Hco-lgc-7 -2.3 Hco	Hco-lgc-34 -2.41 Hco-	<i>Hco-glc-5 -</i> 2.56 <i>Hco</i>	N2	Down-regu					Hco-lgc-39 1.11	<i>Hco-acc-2</i> 1.15	Hco-lgc-55 2.64 Hco-	N2	<u>Up-regula</u>	
	псо-аст-24 - 1.44 Hco-des-2 - 1.27	Hco-lgc-44 -1.14			Hco-lgc-7 -2.55	Hco-lgc-34 -1.19	Hco-glc-5 -1.47	N5	Down-regulated in MHco4(WRS)							Hco-lgc-55 2.74	N5	Up-regulated in MHco4(WRS)	
	Hco-des-2 -1.27	Hco-lgc-44 -1.14				Hco-lgc-34 -1.19		N5 LPGs								Hco-lgc-55 2.74	N5 LPGs		Ligand-g
Hco-eat-2X Hco-acr-15	דרט-עטר-3 Hco-lgc-44	_	Hco-lgc-9	Hco-lgc-43	Hco-lgc-33	L9 Hco-glc-5	Hco-lgc-7			Hco-glc-2	Hco-mptl-1	Hco-acc-1	Hco-lgc-41	Hco-acr-б	Hco-lgc-55	'4 Hco-lgc-3			Ligand-gated Ion Channels
	-44 -1.5		<i>:-9</i> -2.26	-43 -2.66	-33 -2.99		-7 -4.48	N2	Down	-2 1.06		<i>c</i> -1 1.53	-41 1.58	r-6 1.73	-55 2.36	5-3 6.83	N2	<u>Up-r</u>	S
	нсо-Igc-44 Нсо-Igc-44	Hco-acr-24 Hco-aar-3	Hco-lgc-9	Hco-lgc-43	Hco-lgc-33	Hco-glc-5	Hco-lgc-7	N5	Down-regulated in MHco10(CAVR)		mtpl-1		Hco-lgc-41	Нсо-аст-б	Hco-lgc-55	Hco-lgc-3	N5	Up-regulated in MHco10(CAVR)	
	-1.93	-2.17 -1 60	-2.15	-1.37	-2.91	-1.88	-4.3		Hco10(CAV		1.32		1.48	1.53	2.33	5.87		co10(CAVR	
	분기	Hco-	Hco-lgc-9		Hco-Igc-33			N5 LPGs	<u>(R)</u>		Hco-mptl-1		Hco-lgc-41	Hco-acr-6	Hco-lgc-55	Hco-lgc-3	N5 LPGs	12	
	нсо-ууг-з Hco-lgc-44	Hco-acr-24 Hco-acr-2	1 <i>c-9</i>		33			.PGs			1		1	01	ы	~~	PGs		

										-1.07	Hco-abt-7
						-1.24	Hco-pmp-2	-1.24	Hco-pmp-2	-1.29	Hco-pmp-2
				-1.02	Hco-pmp-7	-1.3	Hco-pgp-11	-1.3	Hco-pgp-11	-1.32	Hco-pgp-11
				-1.24	Hco-pgp-9			-1.38	Hco-pgp-16	-1.33	Hco-pgp-16
				-1.5	Hco-pgp-3					-1.4	Hco-abt-2
				-1.57	Hco-pgp-16			-1.13	Hco-pgp-9	-1.45	Hco-pgp-9
		4	Hco-pmp-4	-1.72	Hco-pmp-4	-1.23	Hco-abcf-1X	-1.23	Hco-abcf-1X	-1.53	Hco-abcf-1X
		-1.36	Hco-abt-2	-1.76	Hco-abt-2			-1.21	Hco-abt-4	-1.59	Hco-abt-4
		-1.36	Hco-abcf-1X	-1.9	Hco-abcf-1X	-2.06	Hco-pmp-6	-2.06	Нсо-ртр-б	-1.8	Hco-pmp-6
-1.77	Hco-pmp-6	-1.77	Hco-pmp-6	-2.11	Нсо-ртр-б			-1.03	Hco-pmp-4	-1.89	Hco-pmp-4
	N5 LPGs		N5		N2		N5 LPGs		N5		N2
	<u>/R)</u>	1co10(CA)	Down-regulated in MHco10(CAVR)	Down			<u>(S</u>	1Hco4(WR	Down-regulated in MHco4(WRS)	Dow	
				1.1	Hco-abt-11						
				1.14	Hco-wht-5.1						
				1.27	Hco-mrp-4						
				1.28	Hco-abt-12						
				1.28	Hco-pgp-10						
				1.38	Hco-haf-9						
1.13	Hco-wht-5.2	1.13	Hco-wht-5.2	1.42	Hco-wht-5.2						
1.11	Hco-ced-7	1.11	Hco-ced-7	1.5	Hco-ced-7					1.01	Hco-mrp-4
1.31	Hco-wht-2	1.31	Hco-wht-2	1.71	Hco-wht-2	1.02	Hco-abcf-1	1.02	Hco-abcf-1	1.02	Hco-abcf-1
1.07	Hco-abt-10	1.07	Hco-abt-10	1.85	Hco-abt-10					1.11	Hco-abt-11
1.26	Hco-pgp-11	1.26	Hco-pgp-11	1.94	Hco-pgp-11					1.25	Hco-mrp-7
		1.71	Hco-mrp-3	2.54	Hco-mrp-3					1.48	Hco-abt-10
2.07	Hco-wht-4	2.07	Hco-wht-4	2.68	Hco-wht-4	1				1.65	Hco-abt-12
	N5 LPGs		N5		N2		N5 LPGs		N5		N2
	22	2010(CAVF	Up-regulated in MHco10(CAVR)	Up-r			<u>.</u>	Hco4(WRS)	Up-regulated in MHco4(WRS)	<u>-qU</u>	
					sporters	ABC Transporters					
										-1.01	Hco-lgc-42
				-1.01	Hco-lgc-45					-1.02	Hco-acr-15
				-1.13	Hco-acr-11					-1.05	Hco-acr-7
				-1.13	Hco-acc-2	-1.3	Hco-acr-8	-1.3	Hco-acr-8	-1.06	Hco-acr-8
				-1.26	Hco-lgc-34					-1.06	Hco-lgc-50

## Supplementary Tables.

# Supplementary Table S1. Data point values associated with Figure 4.

0	<.5%	.5 to 1 %	1 to 2 %	2 to 5%	>5%	SNP category	
1.24	1.30	1.43	1.67	1.81	1.71	N2 to N5	MHc
0.62	0.63	0.65	0.67	0.73	0.90	N2 to N5 N5 to N10	MHco3(ISE)
0.94	1.02	1.13	1.36	1.70	2.00	N2 to N5 N5 to N10	MHco₄
0.70	0.81	0.82	0.91	1.01	1.31	N5 to N10	1Hco4(WRS)
0.96	1.02	1.14	1.33	1.71	1.86	N2 to N5 N5 to N1	MHco1(
0.72	0.82	0.90	0.89	0.99	1.29	N5 to N10	MHcol0(CAVR)

contrasted by compiled numbers for genes of only the low-polymorphic gene categories, i.e. both 0 to 2% categories and the 0% category. the average of difference in expression values of all expressed genes in each SNP rate difference category are shown at all SNP mapping allowances N2, N5, N10. B) Compiled numbers for genes of all categories are shown, differentially expressed in each of five different magnitudes - from > log2 2X fold-change up-regulated, to > log2 2X fold-change down-regulated - are shown. The mean (net) log2 fold-difference in expression (NDE), representing genes of each SNP rate difference category at SNP mapping allowances N2, N5, N10. Of expressed genes, the number of genes showing no differential expression (DE) in MHco4(WRS) vs. MHco3(ISE), and the number of genes Supplementary Table S2. A) Genes were classified based on their SNP rate difference in MHco4(WRS) relative to MHco3(ISE). Genes were grouped into seven SNP rate difference categories from extreme rates of 5 to 15% in both directions, to genes showing SNP rate differences of zero. The total number of genes, and the numbers within this total classified by DESeq2 as: unexpressed, showing low counts, and the number expressed are shown for

Α.

	5 to 1 MF	5 to 15% higher in MHco4(WRS)	s) in	2 to MH	2 to 5% higher in MHco4(WRS)	r in S)	0 to	0 to 2 % higher in MHco4(WRS)	S)		0%		0 to : M	0 to 2 % higher in MHco3(ISE)	U H	2 to M	2 to 5% higher in MHco3(ISE)	) iii	5 to 1: MF	5 to 15% higher in MHco3(ISE)	, rin
	N2	N5	N10	N2	N2	N10	N2	N2	N10	N2	N2	N10	N2	N2	N10	N2	N5	N10	N2	N2	N10
Total		300			3,463			12,396			3,977			4,408			407			86	
Number unexpressed	94	86	76	542	470	427	1,415	1,201	1,151	1,014	935	901	513	434	406	83	70	63	39	37	33
Number low counts	124	144	150	1,002	1,210	1,211	3,398	4,044	4,035	1,478	1,711	1,711	1,249	1,424	1,391	141	166	167	30	35	38
Number expressed	82	70	74	1,919	1,783	1,825	7,583	7,151	7,210	1,485	1,331	1,365	2,646	2,550	2,611	183	171	177	29	26	27
Number showing no DE	42	47	47	1,019	1,078	1,264	5,029	5,086	5,342	1,000	1,008	1,103	1,655	1,806	1,955	131	129	133	22	17	22
UP > log2 2X	0	-	-	6	1	-	44	27	20	10	4	з	30	Ξ	6	4	ω	2	2	0	0
UP < log2 2X, > log2 1X	1	-	-	12	26	36	229	166	157	99	45	32	199	96	85	26	14	11	2	4	2
DE under the log2 1X threshold	0	0	0	250	303	281	1,420	1,287	1,222	313	204	169	586	516	471	12	19	24	2	S	2
DOWN < log2 2X, > log2 1X	14	10	18	429	302	211	660	515	431	51	64	55	133	104	85	7	S	6	-	0	-
DOWN > log2 2X	25	Ξ	7	203	73	32	201	70	38	12	6	ω	43	17	9	S)	-	-	0	0	0
Net log2 fold difference in expression (NDE)	-1.331 -1.004	-1.004	-0.682	-0.846	-0.51	-0.316	-0.174	-0.13	-0.096	0.184	0.035	-0.01	0.128	0.06	0.03	0.323	0.234	0.162	0.307	0.305	0.145

 Full Totals
 Within 2% totals

 N2
 N5
 N10
 N2
 N5

 Total
 25,049
 20,781
 20,781

Β

Net log2 fold differences in expression (NDE)	DOWN > log 2 2X	DOWN < log2 2X, > log2 1X	DE under the log2 1X threshold	UP < log2 2X, > log2 1X	UP > log 2 2X	Number no DE	Number expressed	Number low counts	Number unexpressed
-1.409	487	1,295	2,583	568	96	8,898	13,927	7,422	3,700
-1.01	178	1,000	2,334	352	47	9,171	13,082	8,734	3,233
-0.767	90	807	2,169	324	33	9,866	13,289	8,703	3,057
0.138	256	844	2,319	527	84	7,684	11,714	6,125	2,942
-0.035	93	683	2,007	307	42	7,900	11,032	7,179	2,570
-0.076	50	571	1,862	274	29	8,400	11,186	7,137	2,458

Supplementary Table S3. Total number of differentially expressed genes (with adjusted p-values < 0.05 as determined by *DESeq2*) observed in each pairwise strain comparison, at each of the three different map allowances (N2, N5, N10). The number of genes differentially expressed at both > 1 log2 fold, and > 2 log2 fold thresholds are shown. The number of genes up- and down-regulated are also shown along with totals of both.

	MHco4(W	RS) vs. MH	co3(ISE)	MHco10(CA	MHco10(CAVR) vs. MHco3(ISE)	lco3(ISE)	MHco4(WRS)	) vs. MHco1(	)(CAVR)
	N2	N2 N5 N10	N10	N2	N5	N10	N2 N5 N10	N5	N10
> 1 log2 fold up-reg.	664	399	355	1178	834	734	1011	447	302
> 1 log2 fold down-reg.	1783	1188	897	2282	1473	1116	968	544	442
Total > 1 log2 fold	2447	1587	1252	3460	2307	1850	1979	991	744
> 2 log2 fold up-reg.	96	46	33	288	146	97	264	59	32
> 2 log2 fold down-reg.	487	179	90	833	324	189	206	77	41
Total > 2 log2 fold	583	225	123	1121	470	286	470	136	73

Supplementary Table S4. *H. contortus* low-polymorphic gene models present in the UniProt Knowledgebase that are differentially expressed at > 4X fold-change in each pairwise strain comparison. Log2 fold differential expression is shown with length of protein sequence along side 'Protein names' and 'Gene ontology (GO)' descriptors as denoted on the UniProt Knowledgebase.

₽
Up-regulated i
in MHc
:04(WRS
5) vs MHco3
(ISE)

אי סא-ופצמומנכמ ווו ואורנט+(אעטס) אס ואורנטס(וסב)		ici)conuivi	-	
Gene ID	log2 fold D.E.	Length	log2 fold D.E. Length Protein names	Gene ontology (GO)
HCOI_00655600	4.67	110	110 Zinc finger domain containing protein	zinc ion binding [GO:0008270]
HCOI_00444600	3.79	359	7TM GPCR domain containing protein	integral component of membrane [GO:0016021]; G-protein coupled receptor activity [GO:0004930]
HCOI_01404300	3.49	1235	Dsec\GM13241-PA	
HCOI_00355800	3.45	293	Uncharacterized protein	integral component of membrane [GO:0016021]
HCOI_00088900	3.27	361	Protein UNC-2, isoform c	calcium ion binding [GO:0005509]
HCOI_01590000	2.96	83	Uncharacterized protein	integral component of membrane [GO:0016021]
HCOI_01431800	2.8	342	Peptidase C1A domain containing protein	cysteine-type peptidase activity [GO:0008234]
HCOI 00634600	2.76	231	231 Uncharacterized protein (Fragment)	integral component of membrane [GO:0016021]; G-protein coupled receptor activity [GO:0004930]

Gene ontology (GO)	MHco3(ISE) Length Protein names	<b>'s MHco3(IS</b> Length	in MHco4(WRS) v log2 fold D.E.	B. Down-regulated in MHco4(WRS) vs MHco3(ISE) Gene ID log2 fold D.E. Length Pr
actin cytoskeleton organization [GO:0030036]	Diaphanous GTPase-binding and Diaphanous FH3 and Actin-binding FH2 domain containing protein	972	2.01	HCOI_01875600
cytoskeleton [GO:0005856]	Pleckstrin homology and Unconventional myosin plant kinesin protein non-motor protein conserved region MyTH4 and FERM central domain containing protein	1121	2.02	HCOI_00850700
	Uncharacterized protein	315	2.02	HCOI_02043300
asparagine synthase (glutamine-hydrolyzing) activity [GO:0004066]; transferase activity [GO:0016740]; asparagine biosynthetic process [GO:0006529]; glutamine metabolic process [GO:0006541]	Glutamine amidotransferase and Asparagine synthase domain containing protein	847	2.05	HCOI_02159500
	Uncharacterized protein	243	2.05	HCOI_02147600
ribosome [GO:0005840]; structural constituent of ribosome [GO:0003735]; translation [GO:0006412]	Ubiquitin and Ribosomal protein L40e domain containing protein (Uncharacterized protein)	128	2.07	HCOI_00762800
	Uncharacterized protein (Fragment)	326	2.1	HCOI_01504900
zinc ion binding [GO:0008270]	Zinc finger domain containing protein	785	2.1	HCOI_01272300
	GYF domain containing protein	188	2.12	HCOI_00793300
	Calponin actin-binding domain containing protein	243	2.16	HCOI_01416100
	Protein VAP-1, isoform a	178	2.22	HCOI_02003600
	Uncharacterized protein	362	2.27	HCOI_01737000
integral component of membrane [GO:0016021]; G-protein coupled receptor activity [GO:0004930]	7TM GPCR domain containing protein (Fragment)	260	2.29	HCOI_01832400
integral component of membrane [GO:0016021]; neurotransmitter:sodium symporter activity [GO:0005328]	Transporter	467	2.31	HCOI_02042400
integral component of membrane [GO:0016021]; voltage-gated ion channel activity [GO:0005244]	Ion transport and Voltage-dependent calcium channel domain containing protein (Fragment)	1005	2.36	HCOI_00142200
	Uncharacterized protein	102	2.37	HCOI_01789300
	Uncharacterized protein	1593	2.41	HCOI_00475800
	Uncharacterized protein	141	2.43	HCOI_00007400
	Uncharacterized protein	87	2.47	HCOI_01022300
	Armadillo/beta-catenin-like repeat family	459	2.52	HCOI_00293100
cell junction [G0:0030054]; integral component of membrane [G0:0016021]; postsynaptic membrane [G0:0045211]; extracellular-glutamate-gated ion channel activity [G0:0005234]; ionotropic glutamate receptor activity [G0:0004970]	Glutamate receptor and lonotropic glutamate receptor domain containing protein	711	2.54	HCO1_01355500
	Protein F54D5.4 (Fragment)	118	2.54	HCOI_00063700
zinc ion binding [GO:0008270]	Zinc finger domain containing protein	180	2.58	HCOI_00007900
ATP binding [GO:0005524]; protein kinase activity [GO:0004672]	Tau-tubulin kinase 1	209	2.59	HCOI_02045800
	Protein OSR-1	289	2.63	HCOI_02043200
cholinesterase activity [GO:0004104]	Carboxylic ester hydrolase (EC 3.1.1)	459	2.66	HCOI_01942400
integral component of membrane [GO:0016021]; lysozyme activity [GO:0003796]; carbohydrate metabolic process [GO:0005975]; cell wall macromolecule catabolic process [GO:0016998]; peptidoglycan catabolic process [GO:0009253]	Glycoside hydrolase domain containing protein	252	2.69	HCOI_00295200
cell junction [GO:0030054]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; synapse [GO:0045202]; extracellular ligand-gated ion channel activity [GO:0005230]	LGC-55 Ligand-gated chloride channel (Neurotransmitter-gated ion- channel ligand-binding and Neurotransmitter-gated ion-channel transmembrane region domain containing protein)	525	2.74	HCOI_00162900

	Bromodomain transcription factor and Transcription factor THID domain containing protein	426	-2.05	HCOI_01791600
extracellular space [GO:0005615]; peptidase activity [GO:0008233]	Protease inhibitor 14 domain containing protein	351	-2.05	HCOI_01440300
	Uncharacterized protein	407	-2.06	HCOI_02055300
integral component of membrane [GO:0016021]; ATP binding [GO:0005524]; ATPase activity, coupled to transmembrane movement of substances [GO:0042626]	Uncharacterized protein	594	-2.06	HCOI_00272400
extracellular space [GO:0005615]; peptidase activity [GO:0008233]	Protease inhibitor 14 domain containing protein	187	-2.06	HCOI_00927000
DNA binding [GO:0003677]; DNA-directed RNA polymerase activity [GO:0003899]; transcription, DNA- templated [GO:0006351]	DNA-directed RNA polymerase subunit (EC 2.7.7.6) (Fragment)	617	-2.08	HCOI_01152300
heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	175	-2.1	HCOI_01772600
	Uncharacterized protein	252	-2.1	HCOI_00296600
integral component of membrane [GO:0016021]; G-protein coupled peptide receptor activity [GO:0008528]	7TM GPCR domain containing protein	346	-2.11	HCOI_02174400
	Uncharacterized protein	204	-2.11	HCOI_00031900
	BTB:POZ and BTB Kelch-associated and Kelch repeat type 1 domain containing protein	580	-2.12	HCOI_01262900
	Protein F10E7.6	150	-2.14	HCOI_01953600
metalloendopeptidase activity [GO:0004222]	Peptidase M12A domain containing protein	296	-2.14	HC01_01522400
integral component of membrane [GO:0016021]	Uncharacterized protein	593	-2.14	HCOI_00090500
	Heat shock protein Hsp20 domain containing protein	140	-2.15	HCOI_00209700
ATP binding [GO:0005524]; ATP-dependent peptidase activity [GO:0004176]; serine-type endopeptidase activity [GO:0004252]; protein catabolic process [GO:0030163]	Peptidase S16 domain containing protein	318	-2.15	HCOI_01705900
integral component of membrane [GO:0016021]; sodium:dicarboxylate symporter activity [GO:0017153]	Sodium:dicarboxylate symporter domain containing protein	517	-2.15	HCOI_00955600
heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	175	-2.16	HCOI_01772400
integral component of membrane [GO:0016021]; transferase activity [GO:0016740]; fatty acid biosynthetic process [GO:0006633]	Elongation of very long chain fatty acids protein (EC 2.3.1.199) (Very- long-chain 3-oxoacyl-CoA synthase)	284	-2.19	HCOI_00023600
	Protein CDR-4	133	-2.2	- HCOI_01414000
	Uncharacterized protein	198	-2.23	HCOI 01840900
transferase activity [GO:0016740]	Glutathione S-transferase domain containing protein (Fragment)	164	-2.25	HCOI_00998000
	CRE-TWK-11 protein	434	-2.28	HCOI_01950100
carbohydrate binding [GO:0030246]	C-type lectin and Fibrinogen domain containing protein	318	-2.28	HCOI_00892600
	Uncharacterized protein	195	-2.28	HCOI_01021400
lipid binding [GO:0008289]	Nematode fatty acid retinoid binding domain containing protein	179	-2.3	HCOI_00908800
	Heat shock protein Hsp20 domain containing protein	139	-2.31	HCOI_00209900
	Uncharacterized protein	145	-2.31	HCOI_00708200
	p15	135	-2.31	HCOI_00360100
	Activation associated secreted protein	144	-2.32	HCOI_00839100
	Heat shock protein Hsp20 domain containing protein	147	-2.32	HCOI_00915100
	Uncharacterized protein	153	-2.33	HCOI_02105800
H4/H2A histone acetyltransferase complex [GO:0043189]; regulation of transcription, DNA-templated [GO:0006355]	CT20 domain containing protein	196	-2.37	HCOI_01235600
	Uncharacterized protein	418	-2.37	HCOI_00007300

				9	
2.04168Uncharacterized protein2.03449SCP extracellular domain containing protein2.02360Incharacterized protein2.02237Metridin ShK toxin domain containing protein2.01237Metridin ShK toxin domain containing protein2.01488Major facilitator superfamily MrS-1 domain containing protein2.01254Pentidiase M12A domain containing protein2.01254Vertidiase M12A domain containing protein2.01254Pentidiase M12A domain containing protein2.02254Vertidia annesIndez roteinSerrey Protein names3.63.6Uncharacterized protein3.7417Uncharacterized protein3.83.10Uncharacterized protein3.113.12Uncharacterized protein3.123.15Uncharacterized protein3.183.10Uncharacterized protein3.19744Uncharacterized protein3.10Protein FIRE-73.113.14Uncharacterized protein3.123.14Uncharacterized protein3.143.10Vertein containing protein3.15Uncharacterized protein3.14143Uncharacterized protein3.15Uncharacterized protein3.16Vertein KBE-7, isoform C (Fragment)3.17000Protein KBE-7, isoform C (Fragment)3.183.10Vertein containing protein3.1974Uncharacterized protein	integral component of membrane [GO:0016021]	Uncharacterized protein	238	2.82	HCOI_00803300
2.04168Uncharacterized protein2.03449SCP extracellular domain containing protein2.02160Uncharacterized protein2.02160Peptidase C13 domain containing protein2.02237Metridin ShK toxin domain containing protein2.01619Semaphonin CD100 antigen and Plexin domain containing protein2.01264Uncharacterized protein2.01264Veptidase M12A domain containing protein2.01264Veptidase M12A domain containing protein2.01164Veptidase M12A domain containing protein2.01164Veptidase M12A domain containing protein2.02164Veptidase M12A domain containing protein3.01164Veptidase D104.1 domain containing protein3.47417Uncharacterized protein (Fagment)3.48305Ventaracterized protein (Fagment)3.49314Uncharacterized protein3.41112Uncharacterized protein3.42345Ventaracterized protein3.43345Uncharacterized protein3.44114Uncharacterized protein3.55345Uncharacterized protein3.61346Protein FRPK73.72345Uncharacterized protein3.74345Uncharacterized protein3.75346Uncharacterized protein3.76174Uncharacterized protein3.77347Uncharacterized protein3.78342Vertein KNBK7		Uncharacterized protein	257	2.83	HCOI_00412100
2.04168Uncharacterized protein2.0349SCP extracellular domain containing protein2.02160Uncharacterized protein2.02210Peptdase C13 domain containing protein2.02217Metridin SKK toxin domain containing protein2.01619Semaphorin CD100 antigen and Plexin domain containing protein2.01620Incharacterized protein2.01620Najor facilitator superfamily MF5-1 domain containing protein2.01264Uncharacterized protein2.01264Uncharacterized protein2.01264Uncharacterized protein3.01264Uncharacterized protein (Fagment)3.13112Uncharacterized protein (Fagment)3.25219Uncharacterized protein (Fagment)3.26219Uncharacterized protein (Fagment)3.27310Uncharacterized protein3.28219Uncharacterized protein3.29310Uncharacterized protein3.41112Uncharacterized protein3.42143Uncharacterized protein3.43314Uncharacterized protein3.41315Uncharacterized protein3.42314Uncharacterized protein3.43314Uncharacterized protein3.44124Uncharacterized protein3.45130Uncharacterized protein3.41320Uncharacterized protein3.42320Uncharacterized protein3.43<	aspartic-type endopeptidase activity [GO:0004190]; nucleic acid binding [GO:0003676]; zi [GO:0008270]	Uncharacterized protein	959	2.84	HCOI_01226300
2.04168Uncharacterized protein2.0349GCP extracellular domain containing protein2.03180Apyrase domain containing protein2.02160Uncharacterized protein2.01207Retridin ShK toxin domain containing protein2.01619Semaphorin CD100 antige and Plexin domain containing protein2.01610Semaphorin CD100 antige and Plexin domain containing protein2.01620Uncharacterized protein2.01630Major facilitator superfamily MF5-1 domain containing protein2.0164Uncharacterized protein2.01764Uncharacterized protein3.02714Uncharacterized protein (Fagment)3.41112Uncharacterized protein3.42764Uncharacterized protein3.55714Uncharacterized protein3.13764Uncharacterized protein3.14121Uncharacterized protein3.15764Uncharacterized protein3.16764Uncharacterized protein3.17764Uncharacterized protein3.18764Uncharacterized protein3.19764Uncharacterized protein3.10764Uncharacterized protein3.111251433.127643.137643.147643.157143.16Protein KR875, Saform c (Fragment)3.177243.181003.19Protein KR87	kinase activity [GO:0016301]	Uncharacterised kinase D1044.1 domain containing protein	151	2.91	HCOI_01337800
4.04168Uncharacterized protein2.03449SCP extracellular domain containing protein2.03450Apyrase domain containing protein2.02160Uncharacterized protein2.02237Metridin SMK toxin domain containing protein2.01619Semaphorin CD100 antigen and Plexin domain containing protein2.01488Major facilitator superfamily MF5-1 domain containing protein3.01164Uncharacterized protein (Fragment)3.02174Uncharacterized protein (Fragment)3.13112Uncharacterized protein3.14112Uncharacterized protein3.15174Uncharacterized protein3.18174Uncharacterized protein3.18174Uncharacterized protein3.18174Uncharacterized protein3.19164Uncharacterized protein3.10174Uncharacterized protein3.11174Uncharacterized protein3.12174Uncharacterized protein3.	integral component of membrane [GO:0016021]; G-protein coupled receptor activity [GO:	7TM GPCR domain containing protein	359	2.92	HCOI_00444600
2.04168Uncharacterized protein2.03449SCP extracellular domain containing protein2.02160Vncharacterized protein2.022.16Peptidase C13 domain containing protein2.022.37Metridin ShK toxin domain containing protein-2.016.19Semaphorin CD100 antigen and Plexin domain containing protein-2.012.84Major facilitator superfamily MF5-1 domain containing protein-2.012.84Incharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.84Vncharacterized protein-2.012.941.12Vncharacterized protein(Fragment)3.473.13Vncharacterized protein3.473.141.123.483.15Vncharacterized protein3.493.15Vncharacterized protein3.183.141.123.183.141.143.197.143.107.64Uncharacterized protein3.137.64Uncharacterized protein3.143.141.123.153.141.143.153.141.143.153.141.143		Stem cell self-renewal protein Piwi domain containing protein	69	2.96	HCOI_00190000
2.94168Uncharacterized protein $2.03$ 49SCP extracellular domain containing protein $2.03$ 185Apyrase domain containing protein $2.02$ 160Uncharacterized protein $2.02$ 237Metridin ShK toxin domain containing protein $2.01$ 619Semaphorin CD100 antigen and Plexin domain containing protein $2.01$ 264Uncharacterized protein $3.07$ 107Uncharacterized protein (Fragment) $3.14$ 112Uncharacterized protein $3.14$ 112Uncharacterized protein $3.18$ 219TIM GPCR domain containing protein $3.18$ 219Uncharacterized protein $3.18$ 219Uncharacterized protein $3.18$ 219Uncharacterized protein $3.18$ 219Uncharacterized protein $3.07$ 143Uncharacterized protein $3.07$ 143Uncharacterized protein $3.07$ 143Uncharacterized protein $3.04$ 30143 $3.04$ 310 $3.04$ 310 $3.04$ 310		Protein K08E7.5, isoform c (Fragment)	300	2.97	HCOI_01401500
2.94168Uncharacterized protein2.03449SCP extracellular domain containing protein2.03185Apyrase domain containing protein2.02160Uncharacterized protein2.02237Metridin SIK toxin domain containing protein-2.02237Metridin SIK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01264Uncharacterized protein-2.01264Vincharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Vincharacterized protein-2.01264Vincharacterized protein-2.01264Vincharacterized protein-2.01264Vincharacterized protein-3.01264Vincharacterized protein (Fragment)-3.183.14112Uncharacterized protein-3.29315Uncharacterized protein-3.183.14112Uncharacterized protein-3.18217Uncharacterized protein-3.18213Uncharacterized protein-3.18214Uncharacterized protein-3.19214Uncharacterized protein-3.18215Uncharacterized protein-3.18214Uncharacterized protein-3.2035Protein RPR-7-3.213526-3.2536Protein RPR-7-3.3636Uncharacterized protein-3.37134Unchara		Protein F16C3.2	310	3.04	HCOI_00881700
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02237Metridin Shk toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Peptidase M12A domain containing protein-2.01264Peptidase M12A domain containing protein-2.02254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.02254Peptidase M12A domain containing protein-3.03417Uncharacterized protein (Fragment)-3.6260Uncharacterized protein3.26216Uncharacterized protein3.273181123.383141243.30355Protein FRPR-73.31764Uncharacterized protein3.30143Uncharacterized protein		Uncharacterized protein	362	3.05	HCOI_01737000
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02237Metridin Shk toxin domain containing protein-2.01216Semaphorin CD100 antigen and Plexin domain containing protein-2.01254Najor facilitator superfamily MFS-1 domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Vorbaracterized protein-2.02254Potein names-3.673.674173.6260Uncharacterized protein (Fragment)3.293.10Uncharacterized protein3.293.1017M Opter domain containing protein3.133.14121Uncharacterized protein3.13764Uncharacterized protein		Uncharacterized protein	143	3.07	HCOI_00763200
2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02217Retridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01488Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein (Fragment)-3.6417Uncharacterized protein (Fragment)3.63.62003.6210Uncharacterized protein-3.11112Uncharacterized protein-3.25356Protein FRR-73.18181Uncharacterized protein3.14217Uncharacterized protein		Uncharacterized protein	764	3.13	HCOI_01167300
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02217Metridin SNK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01237Metridin SNK toxin domain containing protein-2.01438Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein (Fragment)-2.013.63.6260-2.013.6260-3.47417Uncharacterized protein (Fragment)-3.473.4747-3.483.25219-3.493.49Uncharacterized protein-3.403.5210-3.552197TM GPCR domain containing protein-3.18181Uncharacterized protein	integral component of membrane [GO:0016021]	Uncharacterized protein	217	3.14	HCOI_01602500
-2.04168Uncharacterized protein-2.0349SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin Shk toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein (Fragment)-2.013.6260Uncharacterized protein (Fragment)-2.013.6260Uncharacterized protein-2.013.6260Uncharacterized protein-2.013.25315Uncharacterized protein-2.013.252197TM GPCR domain containing protein-3.25365Protein FRPR-7		Uncharacterized protein	181	3.18	HCOI_02042500
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin Shk toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01488Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2.013.62603.6260Uncharacterized protein (Fragment)-3.41112Uncharacterized protein-3.252197TM GPCR domain containing protein	integral component of membrane [GO:0016021]	Protein FRPR-7	365	3.25	HCOI_00153600
-2.04       168       Uncharacterized protein         -2.03       449       SCP extracellular domain containing protein         -2.03       185       Apyrase domain containing protein         -2.02       160       Uncharacterized protein         -2.02       216       Peptidase C13 domain containing protein         -2.02       217       Metridin ShK toxin domain containing protein         -2.02       237       Metridin ShK toxin domain containing protein         -2.01       619       Semaphorin CD100 antigen and Plexin domain containing protein         -2.01       48       Major facilitator superfamily MFS-1 domain containing protein         -2.01       264       Uncharacterized protein (protein         -2.01       264       Uncharacterized protein (protein         -2.01       267       Uncharacterized protein (protein (protein)         -2.01       260       Uncharacter	integral component of membrane [GO:0016021]	7TM GPCR domain containing protein	219	3.25	HCOI_01956700
-2.04168Uncharacterized protein-2.0349SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01619Semaphorin cutofianing protein-2.01254Major facilitator superfamily MFS-1 domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Potein names-2.015.874.17-2.014.17Uncharacterized protein (Fragment)-2.015.872.60-3.41174-2.014.17-2.014.17-2.011.12-2.014.17-2.011.12-2.011.12-2.012.54-2.011.12-2.012.54-2.011.12-2.012.54-2.012.54-2.012.54-2.01-2.54-2.01-2.54-2.01-2.54-2.01-2.54-2.01-2.54-2.01-2.54-2.01-2.54-2.01-2.54 <t< td=""><td></td><td>Uncharacterized protein</td><td>315</td><td>3.29</td><td>HCOI_02043300</td></t<>		Uncharacterized protein	315	3.29	HCOI_02043300
-2.04168Uncharacterized protein-2.0349SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01254Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Vortein names-2.015.874.17-2.01264Uncharacterized protein (Fragment)-3.6260Uncharacterized protein-3.6260Uncharacterized protein		Uncharacterized protein (Fragment)	112	3.41	HCOI_00456700
-2.04168Uncharacterized protein-2.0349SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01254Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein (Fragment)-3.6260Uncharacterized protein (Fragment)		Uncharacterized protein	87	3.47	HCOI_01022300
-2.04168Uncharacterized protein-2.0349SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01284Major facilitator superfamily MFS-1 domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Peptidase M12A domain containing protein-2.01254Victairacterized protein-2.01254Peptidase M12A domain containing protein-2.01254Victairacterized protein-2.01254Victairacterized protein-2.01254Victairacterized protein-2.01254Victairacterized protein-2.01254Victairacterized protein-2.01254Victairacterized protein-2.01264Victairacterized protein-2.0127254-2.0128Victairacterized protein-2.0129Victairacterized protein (Fragment)-2.01417Victairacterized protein (Fragment)		Uncharacterized protein	260	3.6	HCOI_02000700
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Lingth-2.01264Peptidase M12A domain containing protein-2.01264Victein names-2.015.87417	kinase activity [GO:0016301]	Uncharacterised kinase D1044.1 domain containing protein	174	4	HCOI_01337900
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01264Uncharacterized protein-2.01264Uncharacterized protein-2.01254Peptidase M12A domain containing protein-2.01264Uncharacterized protein-2.01264Length YEA domain containing protein-2.01264Uncharacterized protein-2.01264Peptidase M12A domain containing protein-2.01264Length YEA domain containing protein	integral component of membrane [GO:0016021]; extracellular ligand-gated ion channel ac [GO:0005230]	Uncharacterized protein (Fragment)	417	5.87	HCOI_00418900
<ul> <li>2.04 I68 Uncharacterized protein</li> <li>2.03 449 SCP extracellular domain containing protein</li> <li>2.03 185 Apyrase domain containing protein</li> <li>2.02 160 Uncharacterized protein</li> <li>2.02 216 Peptidase C13 domain containing protein</li> <li>2.02 237 Metridin ShK toxin domain containing protein</li> <li>2.01 619 Semaphorin CD100 antigen and Plexin domain containing protein</li> <li>2.01 488 Major facilitator superfamily MFS-1 domain containing protein</li> <li>2.01 264 Uncharacterized protein</li> <li>2.01 264 Peptidase M12A domain containing protein</li> <li>2.01 254 Peptidase M12A domain containing protein</li> </ul>	Gene ontology (GO)	Protein names	Length	log2 fold D.E.	Gene ID
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein-2.02237Metridin ShK toxin domain containing protein-2.01619Semaphorin CD100 antigen and Plexin domain containing protein-2.01488Major facilitator superfamily MFS-1 domain containing protein-2.01264Uncharacterized protein-2254Peptidase M12A domain containing protein		SE)	; MHco3(IS	MHco10(CAVR) vs	C. Up-regulated in
<ul> <li>2.04 168 Uncharacterized protein</li> <li>2.03 449 SCP extracellular domain containing protein</li> <li>2.02 160 Uncharacterized protein</li> <li>2.02 216 Peptidase C13 domain containing protein</li> <li>2.02 237 Metridin ShK toxin domain containing protein</li> <li>2.01 619 Semaphorin CD100 antigen and Plexin domain containing protein</li> <li>2.01 488 Major facilitator superfamily MFS-1 domain containing protein</li> <li>2.01 264 Uncharacterized protein</li> </ul>		Peptidase M12A domain containing protein	254	-2	HCOI_00716400
<ul> <li>-2.04 168 Uncharacterized protein</li> <li>-2.03 449 SCP extracellular domain containing protein</li> <li>-2.02 160 Uncharacterized protein</li> <li>-2.02 216 Peptidase C13 domain containing protein</li> <li>-2.01 619 Semaphorin CD100 antigen and Plexin domain containing protein</li> <li>-2.01 488 Major facilitator superfamily MFS-1 domain containing protein</li> </ul>		Uncharacterized protein	264	-2.01	HCOI_00849700
<ul> <li>-2.04 168 Uncharacterized protein</li> <li>-2.03 449 SCP extracellular domain containing protein</li> <li>-2.03 185 Apyrase domain containing protein</li> <li>-2.02 160 Uncharacterized protein</li> <li>-2.02 216 Peptidase C13 domain containing protein</li> <li>-2.02 237 Metridin ShK toxin domain containing protein</li> <li>-2.01 619 Semaphorin CD100 antigen and Plexin domain containing protein</li> </ul>	integral component of membrane [GO:0016021]; transmembrane transport [GO:0055085]	Major facilitator superfamily MFS-1 domain containing protein	488	-2.01	HCOI_00971500
<ul> <li>-2.04 168 Uncharacterized protein</li> <li>-2.03 449 SCP extracellular domain containing protein</li> <li>-2.03 185 Apyrase domain containing protein</li> <li>-2.02 160 Uncharacterized protein</li> <li>-2.02 216 Peptidase C13 domain containing protein</li> <li>-2.02 237 Metridin ShK toxin domain containing protein</li> </ul>	integral component of membrane [GO:0016021]	Semaphorin CD100 antigen and Plexin domain containing protein	619	-2.01	HCOI_01166100
-2.04168Uncharacterized protein-2.03449SCP extracellular domain containing protein-2.03185Apyrase domain containing protein-2.02160Uncharacterized protein-2.02216Peptidase C13 domain containing protein		Metridin ShK toxin domain containing protein	237	-2.02	HCOI_01295900
-2.04     168     Uncharacterized protein       -2.03     449     SCP extracellular domain containing protein       -2.03     185     Apyrase domain containing protein       -2.02     160     Uncharacterized protein	GPI-anchor transamidase complex [GO:0042765]; GPI-anchor transamidase activity [GO:00 activity [GO:0008233]; attachment of GPI anchor to protein [GO:0016255]	Peptidase C13 domain containing protein	216	-2.02	HCOI_02130500
-2.04 168 Uncharacterized protein -2.03 449 SCP extracellular domain containing protein -2.03 185 Apyrase domain containing protein		Uncharacterized protein	160	-2.02	HCOI_00437500
-2.04 168 Uncharacterized protein -2.03 449 SCP extracellular domain containing protein	calcium ion binding [GO:0005509]; pyrophosphatase activity [GO:0016462]	Apyrase domain containing protein	185	-2.03	HCOI_01272800
-2.04 168 Uncharacterized protein	extracellular region [GO:0005576]	SCP extracellular domain containing protein	449	-2.03	HCOI_00651500
		Uncharacterized protein	168	-2.04	HCOI_00709500

zinc ion binding [GO:0008270]	Zinc finger domain containing protein	110	2.05	HCOI_00655600
	Uncharacterized protein	94	2.05	HCOI_01411000
carbohydrate binding [GO:0030246]	Galectin (Fragment)	152	2.05	HCOI_01162700
microtubule [GO:0005874]; ATP binding [GO:0005524]; microtubule motor activity [GO:0003777]; microtubule-based movement [GO:0007018]	Kinesin-like protein	495	2.06	HCOI_00446300
integral component of membrane [GO:0016021]; glucuronosyltransferase activity [GO:0015020]; metabolic process [GO:0008152]	UDP-glucuronosyltransferase (EC 2.4.1.17)	368	2.06	HCOI_01255000
membrane [GO:0016020]; ATP binding [GO:0005524]; ATPase activity [GO:0016887]	Uncharacterized protein (Fragment)	498	2.07	HCOI_01169000
	Uncharacterized protein	437	2.09	HCOI_00767800
	Uncharacterized protein	266	2.09	HCOI_01545500
integral component of membrane [GO:0016021]	Uncharacterized protein	640	2.1	HCOI_00385800
integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; transporter activity [GO:0005215]; ion transport [GO:0006811]	Solute carrier organic anion transporter family member	682	2.1	HCOI_00769700
integral component of membrane [GO:0016021]; potassium channel activity [GO:0005267]	Ion transport 2 domain containing protein	393	2.11	HCOI_00408700
voltage-gated calcium channel complex [GO:0005891]; voltage-gated calcium channel activity [GO:0005245]	Ion transport domain containing protein	683	2.11	HCOI_00088800
integral component of membrane [GO:0016021]; lysozyme activity [GO:0003796]; carbohydrate metabolic process [GO:0005975]; cell wall macromolecule catabolic process [GO:0016998]; peptidoglycan catabolic process [GO:0009253]	Glycoside hydrolase domain containing protein	252	2.12	HCOI_00295200
nucleolus [GO:0005730]; DNA-directed RNA polymerase activity [GO:0003899]; nucleic acid binding [GO:0003676]; zinc ion binding [GO:0008270]; transcription, DNA-templated [GO:0006351]	DNA-directed RNA polymerase subunit	119	2.12	HCOI_00696400
mitochondrion [GO:0005739]; double-stranded DNA binding [GO:0003690]; regulation of transcription, DNA-templated [GO:0006355]	Uncharacterized protein (Fragment)	216	2.12	HCOI_01516900
	Parasitic stage specific protein 1	120	2.12	HCOI_00260300
integral component of membrane [GO:0016021]	Amino acid transporter domain containing protein (Fragment)	380	2.13	HCOI_01621500
collagen trimer [GO:0005581]; integral component of membrane [GO:0016021]; structural constituent of cuticle [GO:0042302]	Nematode cuticle collagen and Collagen triple helix repeat domain containing protein	358	2.14	HCOI_00881600
integral component of membrane [GO:0016021]	Uncharacterized protein	83	2.14	HCOI_01590000
	Uncharacterized protein	277	2.15	HCOI_01428100
integral component of membrane [GO:0016021]	Uncharacterized protein	430	2.15	HCOI_01438100
integral component of membrane [GO:0016021]; neurotransmitter:sodium symporter activity [GO:0005328]	Transporter	565	2.16	HCOI_02042900
	Nucleolar protein 10 (Fragment)	193	2.16	HCOI_01825500
	Uncharacterized protein	326	2.17	HCOI_00980400
	Uncharacterized protein	476	2.17	HCOI_00582100
	Armadillo/beta-catenin-like repeat family	459	2.18	HCOI_00293100
	Uncharacterized protein	67	2.18	HCOI_01140400
nucleic acid binding [GO:0003676]; DNA integration [GO:0015074]	Integrase domain containing protein	583	2.19	HCOI_01226200
	Transcription factor jumonji domain containing protein	401	2.2	HCOI_01901700
	Uncharacterized protein	124	2.23	HCOI_02167300

	Uncharacterized protein	475	-2.64	HCOI_00450400
	Uncharacterized protein	200	-2.66	HCOI 00271700
integral component of membrane [GO:0016021]; transferase activity, transferring hexosyl groups [GO:0016758]; metabolic process [GO:0008152]	UDP-glucuronosyl UDP-glucosyltransferase domain containing protein (Fragment)	294	-2.68	HCOI_00589900
	Uncharacterized protein	195	-2.69	HCOI_01021400
	Protein TAG-307	84	-2.7	HCOI_01388800
	Uncharacterized protein	136	-2.71	HCOI_01240800
	p15	137	-2.71	HCOI_01615000
	Uncharacterized protein (Fragment)	230	-2.74	HCOI_01497600
	Beta-lactamase-related domain containing protein	405	-2.82	HCOI_01170600
membrane [GO:0016020]; galactosyltransferase activity [GO:0008378]; protein glycosylation [GO:0006486]	Glycoprotein-N-acetylgalactosamine	250	-2.85	HCOI_00684000
calcium ion binding [GO:0005509]	EF hand domain containing protein	135	-2.86	HCOI_00694600
ATP binding [GO:0005524]	Actin actin domain containing protein	376	-2.89	HCOI_01137800
	15 kDa excretory/secretory protein	135	-2.89	HCOI_00360200
kinase activity [GO:0016301]	Uncharacterised kinase D1044.1 domain containing protein	804	-2.89	HCOI_00463000
integral component of membrane [GO:0016021]; extracellular ligand-gated ion channel activity [GO:0005230]	Uncharacterized protein (Fragment)	386	-2.91	HCOI_00938300
	Protein VAP-1, isoform a	186	-2.92	HCOI_00905000
extracellular space [GO:0005615]; peptidase activity [GO:0008233]	Protease inhibitor 14 domain containing protein	352	-2.94	HCOI_00621300
metal ion binding [GO:0046872]	Zinc finger domain containing protein	463	-2.97	HCOI_00893400
	Uncharacterized protein	246	-3.02	HCOI_01294600
	Uncharacterized protein	137	-3.1	HCOI_01997300
	Uncharacterized protein	137	-3.13	HCOI_01996700
	Uncharacterized protein	147	-3.17	HCOI_01514600
	Uncharacterized protein	207	-3.29	HCOI_01540300
	Uncharacterized protein	113	-3.31	HCOI_00221000
ribosome [GO:0005840]	Ribosomal protein S32 domain containing protein	112	-3.31	HCOI_01204900
	Uncharacterized protein	418	-3.36	HCOI_00007300
	Uncharacterized protein	96	-3.47	HCOI_00593400
	Uncharacterized protein	289	-3.8	HCOI_00719200
nucleus [GO:0005634]	Uncharacterized protein	313	-4.74	HCOI_01253600
Gene ontology (GO)	Protein names	Length	log2 fold D.E.	Gene ID log2 fold D.E. Length Prot
	22/(FE)			
integral component of membrane [GO:0016021]; sensory perception of chemical stimulus [GO:0007606]	7TM GPCR domain containing protein	324	2.01	HCOI_01984100
	Uncharacterized protein	150	2.02	HCOI_01932100
integral component of membrane [GO:0016021]	Protein M28.8	729	2.03	HCOI_01642000
integral component of membrane [GO:0016021]; potassium channel activity [GO:0005267]	TWiK family of potassium channels protein 7	608	2.03	HCOI_01881900
	Uncharacterized protein	202	2.03	HCOI_00606600
	Protein R09E10.6	466	2.04	HCOI_01429500
integral component of membrane [GO:0016021]; G-protein coupled receptor activity [GO:0004930]	7TM GPCR domain containing protein (Fragment)	485	2.05	HCOI_00792100

		LUC	- C C.	0000001021000
RNA polymerase activity [GO:0003899]; transcription, DNA-templated [GO:0006351]	RNA polymerase Rpb6 domain containing protein	128	-2.22	HCOI_00696100
DNA disastad BNA palamassa II pasa samalay [CO-0000EEEE]. DNA hinding [CO-0003E77]. DNA disastad				
	Uncharacterized protein (Fragment)	1169	-2.23	HC0I_00223400
	Protein Y54G11A.1	502	-2.27	HCOI_01202200
integral component of membrane [GO:0016021]	Uncharacterized protein	342	-2.29	HCOI_01387700
	Heat shock protein Hsp20 domain containing protein	136	-2.29	HCOI_00915300
	Uncharacterized protein	76	-2.29	HCOI_00359200
	BTB:POZ and BTB Kelch-associated and Kelch repeat type 1 domain containing protein	580	-2.33	HCOI_01262900
	Activation associated secreted protein	144	-2.33	HCOI_00839100
heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	175	-2.33	HCOI_01772600
	15 kDa excretory/secretory protein	137	-2.35	HCOI_00514900
	Uncharacterized protein	204	-2.35	HCOI_00031900
nucleic acid binding [GO:0003676]; nucleotide binding [GO:0000166]	RNA recognition motif domain containing protein	87	-2.35	HCOI_01798700
	SH2 motif domain containing protein	183	-2.36	HCOI_00919400
	Venom allergen/ancylostoma secreted protein-like	226	-2.39	HCOI_01667300
integral component of membrane [GO:0016021]	Aquaporin-10	271	-2.4	HCOI_01306000
extracellular space [GO:0005615]; peptidase activity [GO:0008233]	Protease inhibitor 14 domain containing protein	187	-2.43	HCOI_00927000
heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	175	-2.44	HCOI_01772500
integral component of membrane [GO:0016021]	Uncharacterized protein	593	-2.45	HCOI_00090500
metal ion binding [GO:0046872]; oxidoreductase activity [GO:0016491]	Tyrosinase domain containing protein	254	-2.45	HCOI_01868700
	Heat shock protein Hsp20 domain containing protein	165	-2.47	HCOI_00915200
	Uncharacterized protein	146	-2.48	HCOI_02107900
glutathione peroxidase activity [GO:0004602]; response to oxidative stress [GO:0006979]	Glutathione peroxidase	188	-2.49	HCOI_00620700
integral component of membrane [GO:0016021]	BRICHOS domain containing protein	575	-2.5	HCOI_02060300
	Nematode insulin-related peptide domain containing protein	101	-2.5	HCOI_01771500
	Endoglin CD105 antigen domain containing protein	93	-2.51	HCOI_00214700
GPI-anchor transamidase complex [GO:0042765]; GPI-anchor transamidase activity [GO:0003923]; peptidase activity [GO:0008233]; attachment of GPI anchor to protein [GO:0016255]	Peptidase C13 domain containing protein	216	-2.52	HCOI_02130500
aspartic-type endopeptidase activity [GO:0004190]	Peptidase A1 domain containing protein	394	-2.53	HCOI_02033100
	Uncharacterized protein	132	-2.55	HCOI_00621200
	Uncharacterized protein	160	-2.55	HCOI_00437500
collagen trimer [GO:0005581]	Collagen triple helix repeat domain containing protein	272	-2.58	HCOI_01248100
cysteine-type peptidase activity [GO:0008234]	Peptidase C1A domain containing protein	346	-2.58	HCOI_00524200
protein tyrosine phosphatase activity [GO:0004725]	Protein-tyrosine phosphatase domain containing protein	484	-2.59	HCOI_01584300
aspartic-type endopeptidase activity [GO:0004190]	Peptidase A1 domain containing protein	329	-2.6	HCOI_02033000
integral component of membrane [GO:0016021]; transferase activity [GO:0016740]; fatty acid biosynthetic process [GO:0006633]	Elongation of very long chain fatty acids protein (EC 2.3.1.199) (Very- long-chain 3-oxoacyl-CoA synthase)	284	-2.61	HCOI_00023600
extracellular region [GO:0005576]	SCP extracellular domain containing protein	215	-2.61	HCOI_00171700
	Uncharacterized protein	252	-2.64	HCOI_00296600

integral component of membrane [GO:0016021]; kinase activity [GO:0016301]
integral component of membrane [GO:0016021]
Nematode cuticle collagen and Collagen triple helix repeat domain collagen trimer [GO:0005581]; in containing protein cuticle [GO:0042302]
Short-chain dehydrogenase reductase SDR domain containing protein
FAD-dependent pyridine nucleotide-disulphide oxidoreductase domain oxidoreductase activity [GO:001] containing protein
metalloendopeptidase activity [GO:0004222]; zinc ion binding [GO:0008270]; molting cycle, collagen and cuticulin-based cuticle [GO:0018996]
metallopeptidase activity [GO:0008237]
extracellular region [GO:0005576]
extracellular re
cytosol [GO:0005829]; protein urmylation [GO:0032447]; tRNA thio-modification [GO:0034227]; tRNA wobble uridine modification [GO:0002098]
integral component of membrane [GO:0016021]; neurotransmitter:sodium symporter activity [GO:0005328]
integral component of membrane [GO:0016021]
proteasome complex [GO:0000502]
integral component of membrane [GO:0016021]; protein phosphatase inhibitor activity [GO:0004864]; regulation of phosphoprotein phosphatase activity [GO:0043666]; regulation of signal transduction [GO:0009966]
RNA-directed DNA polymerase activity [GO:0003964]
membrane [GO:0016020]; metalloendopeptidase activity [GO:0004222]; cell adhesion [GO:0007155]
extracellular region [GO:0005576]
Myosin head and IQ calmodulin-binding region and Myosin tail domain myosin complex [GO:0016459]; ATP binding [GO:0005524]; motor activity [GO:0003774] containing protein (Fragment)
extracellular region [GO:000557
extracellular space [GO:0005615]
extracellular region [GO:0005576]
metallopeptidase activity [GO:0008237]

integral component of membrane [GO:0016021]; extracellular ligand-gated ion channel activity [GO:0005230]	Uncharacterized protein (Fragment)	386	2.17	HCOI_00938300
	Uncharacterized protein	118	2.19	HC01_02040900
DNA binding [G0:0003677]; DNA-directed RNA polymerase activity [G0:0003899]; transcription, DNA- templated [G0:0006351]	DNA-directed RNA polymerase domain containing protein	108	2.21	HCOI_02076500
ATP binding [GO:0005524]; protein kinase activity [GO:0004672]	Serine threonine protein kinase-related domain containing protein	942	2.22	HCOI_01788300
	Uncharacterized protein	1377	2.23	HCOI_01629200
	Endoglin CD105 antigen domain containing protein	93	2.25	HCOI_00214700
carbohydrate binding [GO:0030246]	C-type lectin and Fibrinogen domain containing protein	371	2.36	HCOI_00892400
integral component of membrane [GO:0016021]; helicase activity [GO:0004386]	DNA RNA helicase domain containing protein (Fragment)	212	2.4	HCOI_02014700
ATP binding [GO:0005524]; ATPase activity [GO:0016887]; microtubule motor activity [GO:0003777]; microtubule-based movement [GO:0007018]	Dynein heavy chain and ATPase associated with various cellular activities domain containing protein	1981	2.44	HCOI_01710300
DNA primase activity [GO:0003896]	DNA primase domain containing protein	488	2.45	HCOI_00682700
extracellular space [GO:0005615]; peptidase activity [GO:0008233]	Protease inhibitor 14 domain containing protein	352	2.52	HCOI_00621300
ATP binding [GO:0005524]; DNA binding [GO:0003677]; DNA topoisomerase type II (ATP-hydrolyzing) activity [GO:0003918]; DNA topological change [GO:0006265]	Uncharacterized protein	83	2.53	HCOI_01155600
	RE55111p	106	2.56	HCOI_01952000
collagen trimer [GO:0005581]	Collagen triple helix repeat domain containing protein	272	2.58	HCOI_01248100
zinc ion binding [GO:0008270]	Zinc finger domain containing protein	110	2.62	HCOI_00655600
integral component of membrane [GO:0016021]	Uncharacterized protein	293	2.71	HCOI_00355800
	Uncharacterized protein	102	2.74	HCOI_00454600
	Uncharacterized protein	137	2.75	HCOI_02011700
	ATP synthase assembly factor FMC1 domain containing protein	174	2.79	HCOI_00374400
ribosome [GO:0005840]	Ribosomal protein S32 domain containing protein	112	2.84	HCOI_01204900
	Zinc finger domain containing protein	185	2.87	HCOI_01236700
collagen trimer [GO:0005581]; integral component of membrane [GO:0016021]; structural constituent of cuticle [GO:0042302]	Nematode cuticle collagen and Collagen triple helix repeat domain containing protein	298	3.03	HCOI_00385500
ATP binding [GO:0005524]; protein kinase activity [GO:0004672]	Tau-tubulin kinase 1	209	3.48	HCOI_02045800
Gene ontology (GO)	AVR) Protein names	MHco10(CA Length	MHco4(WRS) vs I log2 fold D.E.	E. Up-regulated in MHco4(WRS) vs MHco10(CAVR) Gene ID log2 fold D.E. Length Pro
	SCP extracellular domain containing protein	188	-2	HCOI_01600100
collagen trimer [GO:0005581]	Collagen triple helix repeat domain containing protein (Fragment)	107	-2.01	HCOI_01451800
extracellular region [GO:0005576]	SCP extracellular domain containing protein	215	-2.01	HCOI_01986300
integral component of membrane [GO:0016021]; heme binding [GO:0020037]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	297	-2.02	HCOI_01772000
	Uncharacterized protein	89	-2.02	HCOI_01984700
integral component of membrane [GO:0016021]	Uncharacterized protein	204	-2.02	HCOI_01994500
integral component of membrane [GO:0016021]; sodium:dicarboxylate symporter activity [GO:0017153]	Sodium:dicarboxylate symporter domain containing protein	517	-2.03	HCOI_00955600
heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	Globin domain containing protein	175	-2.03	HCOI_01772400

Uncharacterised protein family UPF0005 domain containing protein	integral component of membrane [GO:0016021]
Transcription initiation factor IID domain containing protein	translation initiation factor activity [GO:0003743]; transcription from RNA polymerase II promoter [GO:0006366]
Protein VAP-1, isoform a	
CoA-transferase family III domain containing protein	transferase activity [GO:0016740]
Histone H1 H5 domain containing protein	nucleosome [GO:0000786]; nucleus [GO:0005634]; DNA binding [GO:0003677]; nucleosome assembly [GO:0006334]
Uncharacterized protein	
Uncharacterized protein	
Snf7 domain containing protein	intracellular [GO:0005622]; vacuolar transport [GO:0007034]
Ribosomal protein LGE domain containing protein	ribosome [GO:0005840]; structural constituent of ribosome [GO:0003735]; translation [GO:0006412]
Phosphomannomutase (EC 5.4.2.8)	cytoplasm [GO:0005737]; phosphomannomutase activity [GO:0004615]; GDP-mannose biosynthetic process [GO:0009298]
D(CAVR)	
Length Protein names	Gene ontology (GO)
Uncharacterized protein (Fragment)	integral component of membrane [GO:0016021]; extracellular ligand-gated ion channel activity [GO:0005230]
UDP-glucuronosyltransferase (EC 2.4.1.17)	integral component of membrane [GO:0016021]; glucuronosyltransferase activity [GO:0015020]; metabolic process [GO:0008152]
Mammalian uncoordinated homology 13 and C2 calcium-dependent membrane targeting domain containing protein	
CBN-SPP-18 protein	
Kinesin-like protein	microtubule [GO:0005874]; ATP binding [GO:0005524]; microtubule motor activity [GO:0003777]; microtubule-based movement [GO:0007018]
BTB:POZ and BTB Kelch-associated and Kelch repeat type 1 domain containing protein	
Uncharacterized protein	
DNA-binding RFX domain containing protein	DNA binding [GO:0003677]; regulation of transcription, DNA-templated [GO:0006355]
Lipoxygenase and Polycystin cation channel domain containing protein	integral component of membrane [GO:0016021]; calcium ion binding [GO:0005509]
Protein W03D8.11	
Protein T05A7.1	
Stem cell self-renewal protein Piwi domain containing protein	
Bestrophin domain containing protein	
Uncharacterized protein (Fragment)	
C. briggsae CBR-VAB-8 protein	
7TM GPCR and RNA-directed DNA polymerase (Reverse transcriptase) domain containing protein	integral component of membrane [GO:0016021]; RNA-directed DNA polymerase activity [GO:0003964]
Protein FRPR-7	integral component of membrane [GO:0016021]
Uncharacterized protein (Fragment)	
Protein T08B6.4	integral component of membrane [GO:0016021]
	HCI0633002.14121Transcription initiation factor IID domain containing proteinHCI000633002.1337Potein VAP-1, isoform aHCO00079002.03134Hotomain containing proteinHCO00079002.01134Uncharacterized proteinHCO00079002.012.01145HCO_000876002.012.01140HCO_001330002.012.01140HCO_001330002.012.01140HCO_001330002.012.01140HCO_001330002.01140Hotelin namesHCO_0013500-5.303.01Uncharacterized protein (Fagment)HCO_0013500-4.333.02Uncharacterized protein (Fagment)HCO_00445300-3.434.05Uncharacterized proteinHCO_00445300-3.434.05Uncharacterized proteinHCO_00445300-3.434.05Itsin-like proteinHCO_00445300-3.434.05Uncharacterized proteinHCO_00445300-2.55100Uncharacterized proteinHCO_00445300-2.65114Uncharacterized proteinHCO_00445300-2.65100Uncharacterized proteinHCO_00445300-2.65100Uncharacterized proteinHCO_005600-2.65100Uncharacterized proteinHCO_005600-2.65100Uncharacterized protein (Fagment)HCO_0055000-2.65100Uncharacterized protein (Fagment)HCO_0055000-2.6452

signal transduction [GO:0007165]	Sterile alpha motif SAM and Sterile alpha motif homology 2 and Toll- Interleukin receptor domain containing protein	364	-2	HCOI_01527500
carbohydrate binding [GO:0030246]	Galectin	179	-2.01	HCOI_01904900
ATP binding [GO:0005524]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]	Tyrosine-protein kinase (EC 2.7.10.2)	501	-2.02	HCOI_01931900
	Protein F01F1.3 (Uncharacterized protein)	247	-2.03	HCOI_00792300
	Zinc finger protein	249	-2.03	HCOI_01256400
	Protein CYN-17, isoform a	371	-2.03	HCOI_00040300
ATP binding [GO:0005524]; protein serine/threonine kinase activity [GO:0004674]	Serine threonine protein kinase-related domain containing protein	319	-2.05	HCOI_00084900
integral component of membrane [GO:0016021]	Uncharacterized protein	217	-2.05	HCOI_01602500
integral component of membrane [GO:0016021]	Clc domain containing protein	431	-2.06	HCOI_01597200
integral component of membrane [GO:0016021]	Uncharacterized protein	137	-2.06	HCOI_00366600
integral component of membrane [GO:0016021]; mitochondrion [GO:0005739]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]	Uncharacterized protein	332	-2.06	HCOI_01760800
calcium ion binding [GO:0005509]; iron ion binding [GO:0005506]; manganese ion binding [GO:0030145]; phosphoprotein phosphatase activity [GO:0004721]; detection of stimulus involved in sensory perception [GO:0050906]	Serine/threonine-protein phosphatase (EC 3.1.3.16)	625	-2.06	HCOI_01899200
integral component of membrane [GO:0016021]	7TM GPCR domain containing protein	335	-2.07	HCOI_01602200
hydrolase activity [GO:0016787]	Lipase domain containing protein	202	-2.09	HCOI_02172000
	Uncharacterized protein	112	-2.1	HCOI_00441800
membrane [GO:0016020]; synaptic vesicle [GO:0008021]; exocytosis [GO:0006887]	C2 calcium-dependent membrane targeting domain containing protein	380	-2.11	HCOI_01602300
integral component of membrane [GO:0016021]	7TM GPCR domain containing protein	219	-2.12	HCOI_01956700
	Uncharacterized protein	99	-2.12	HC01_00354000
	Uncharacterized protein	91	-2.14	HCOI_01845500
	Uncharacterized protein	150	-2.14	HCOI_01932100
	Uncharacterized protein	124	-2.15	HCOI_02167300
peptidase activity [GO:0008233]	Protease inhibitor 18 domain containing protein	224	-2.16	HCOI_01052400
integral component of membrane [GO:0016021]; ATP binding [GO:0005524]; ATPase activity, coupled to transmembrane movement of substances [GO:0042626]	Uncharacterized protein (Fragment)	1250	-2.18	HCOI_00622400
translation initiation factor activity [GO:0003743]	S1 domain containing protein	279	-2.19	HCOI_01753400
	CRE-TWK-11 protein	434	-2.2	HCOI_01950100
	Uncharacterized protein	101	-2.22	HCOI_00441900
	SCP extracellular domain containing protein	274	-2.23	HCOI_01191500
integral component of membrane [GO:0016021]	Uncharacterized protein	430	-2.25	HCOI_01438100
carbohydrate binding [GO:0030246]	Galectin	284	-2.28	HCOI_01543000
	Uncharacterized protein	646	-2.41	HCOI_00608600
	Uncharacterized protein	564	-2.42	HCOI_01442300
	Protein K08E7.5, isoform c (Fragment)	300	-2.44	HCOI_01401500
kinase activity [GO:0016301]	Uncharacterised kinase D1044.1 domain containing protein	174	-2.5	HCOI_01337900

Figure 1.








Figure 1 of 5 pdf, (ppt available)












Log2 fold-change difference in expression




Log2 fold-change difference in expression





Number of differentially expressed genes relative to MHco3(ISE) А MHco4(WRS) MHco10(CAVR) Up-regulated 192 157 529 28 13 108 442 334 478 58 35 103 Down-regulated

Number of differentially expressed genes relative to MHco10(CAVR)



C Number of differentially expressed genes relative to MHco4(WRS)

